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Abstract: A new class of inhibitors of tubulin polymerization based on the 2-
alkoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)indole molecular skeleton was synthesized 
and evaluated for antiproliferative activity, inhibition of tubulin polymerization and cell 
cycle effects. The results presented show that the methoxy substitution and location on 
the indole nucleus plays an important role in inhibition of cell growth, and the most 
favourable position for the substituent was at C-6. In addition, a small-size ester function 
(methoxy/ethoxycarbonyl) at the 2-position of the indole core was desirable. Also, 
analogues that were alkylated with methyl, ethyl or n-propyl groups or had a benzyl 
moiety on the N-1 indolic nitrogen retained activity equivalent to those observed in the 
parent N-1H analogues. The most promising compounds of the series were 2-
methoxycarbonyl-3-(3’,4’.5’-trimethoxyanilino)-5-methoxyindole 3f and 1-methyl-2-
methoxycarbonyl-3-(3’,4’.5’-trimethoxyanilino)-6-methoxy-indole 3w, that target tubulin 
at the colchicine site with antitubulin activities comparable to that of the reference 
compound CA-4.  









Microtubules are polymeric structures composed of two structurally similar protein 
subunits, - and -tubulin, arranged head-to-tail to form a linear protofilament, with 13 
protofilaments forming the cylindrical microtubule. They are crucial in a number of 
cellular functions critical to the life cycle of the cell [1, 2].  
The biological importance of microtubules makes them an interesting target for the 
development of clinically useful anticancer drugs [3, 4], as has been demonstrated by the 
therapeutic use of vinca alkaloids and taxanes [5-7]. Compounds such as vinca alkaloids 
that are able to interfere with the assembly of tubulin into microtubules have antimitotic 
activity and are referred to as tubulin polymerization inhibitors [8]. In contrast, taxanes 
prevent microtubule disassembly and are classified as microtubule stabilizing agents [9]. 
Numerous chemically diverse antimitotic agents, many of which are natural products, 
interact specifically with tubulin and alter tubulin polymerization [10-12]. Combretastatin 
A-4 (CA-4, 1a, Figure 1), isolated from the bark of the South African tree Combretum 
caffrum, is one of the well-known natural tubulin binding molecules affecting 
microtubule dynamics [13]. CA-4 potently inhibited the polymerization process of 
tubulin to microtubules by binding to the colchicine site on tubulin, hampering the 
formation of the mitotic spindle [14]. CA-4 also displayed potent cytotoxic activities 
against a wide variety of human cancer cell lines at low nanomolar concentrations, 
including those that are multidrug-resistant [15]. The water-soluble disodium phosphate 
prodrug of CA-4 (CA-4P, 1b) showed promising results as a tumor vascular-disrupting 
agent (VDA) in phase II clinical trials for multi-drug combination antitumor therapy [16-
18]. Its structural simplicity, along with its ability to selectively damage tumor 
neovasculature, makes CA-4 of great interest from the medicinal chemistry point of 
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view, and a wide number of CA-4 analogues have been developed and evaluated in 
structure-activity relationship (SAR) studies [19-22]. 
Several synthetic molecules have been also reported as tubulin destabilizing agents, 
acting as inhibitors of tubulin polymerization [23-27]. In this respect, a literature search 
revealed past [28-31] and recent [32-34] studies in which the indole molecular skeleton 
has been widely employed as a versatile pharmacophore for the development of 
chemically diverse small molecules identified as tubulin polymerization inhibitors.   
Among the synthetic inhibitors of tubulin polymerization having an indole as their core 
nucleus, it was observed that the presence of an alkoxycarbonyl function at the 2-
position of the N-1-H-indole system was essential for potent antitumor activity and for 
potent inhibition of tubulin polymerization. A series of 2-alkoxycarbonyl-3-(3’,4’,5’-
trimethoxy-phenylthio/benzoyl/benzyl)-1H-indole derivatives with general structure 2 
was reported as antitubulin agents by Silvestri and co-workers [35-37]. These 
compounds were characterized by the presence of an electron-withdrawing atom (Cl or 
Br) or the electron-donating methoxy group at the C-5 position and a 
methoxy/ethoxycarbonyl moiety at the C-2 position of the indole ring, with the greatest 
inhibitory effects on MCF-7 cells observed for either sulfur or carbonyl derivatives 
bearing a 2-methoxycarbonyl group at the 2-position of the indole.  
Therefore, in continuation on our work on anticancer agents based on the indole 
skeleton, in an effort to further improve activity and extend the SAR evaluation of 
derivatives with general structure 2, we focused our attention on exploring the possibility 
of replacing the sulfur, carbonyl or methylene bridging units between the 3-position of 
the indole nucleus and the 3’,4’,5’-trimethoxyphenyl or 3’,5’-dimethoxyphenyl moieties 
by a bioisosteric anilinic nitrogen (NH) moiety with hydrogen-bond accepting and 
donating capability to furnish a new series of 2-alkoxycarbonyl-3-(3’,4’,5’-
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trimethoxy/2’,5’-dimethoxyanilino)indole derivatives with general structure 3 modified 
with respect to positions C-5 to C-7 with methyl, chloro or methoxy moieties. 
Once the 3’,4’,5’-trimethoxyanilino or 3’,5’-dimethoxyanilino moiety was placed at the 
3-position of the indole core, we explored the SAR by examining the following 
modifications:  
a) various substitutions at the N-1 position (we selected hydrogen, methyl, ethyl, propyl 
or benzyl to examine the steric effect of substituent R3). 
b) the effect of the electron-withdrawing 2-alkoxycarbonyl group esters with either a 
linear or a branched alkoxy chain (R2=methyl, ethyl, n-propyl, i-propyl, t-butyl or benzyl)  
c) the location of the methoxy group (R1) at the 5-, 6- or 7-position of the indole nucleus 
as well as the presence of an electron-releasing methyl or electron-withdrawing chlorine 
atom at the C-5 and C-6 position, respectively. 
Recently, a series of 2-aroyl-3-aminopyrimidine-1H-indole derivatives with general 
structure 4, possessing a morpholine or thiomorpholine linked to the C-2 position of the 
pyrimidine ring were synthesized by Zhao et al [38]. Among the tested compounds, the 
most promising was derivative 4a, with IC50 values of 0.29, 4.04, and 9.48 M against 
the MCF-7, HeLa, and HCT116 cell lines, respectively. The same derivative also 
exhibited the most potent anti-tubulin activity, with an IC50 of 19.3 M in their tubulin 
polymerization assay.  
The same authors also reported a series of 2-aroyl-3-(3’,4’,5’-trimethoxybenzoyl)amino-
1H-indoles with general structure 5 incorporating an amido bridge into the 3-position of 
the indole nucleus [39]. The most active derivative 5a inhibited the growth of the T47D, 
BT549, and MDA-MB-231 cell lines with IC50 values of 0.04, 3.17, and 6.43 M, 
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respectively, and showed moderate antitubulin polymerization activity with an IC50 of 9.5 
M.  
 
Figure 1. Structures of CA-4 (1a) and CA-4P (1b). General structures 2, 4 and 5 of various known 
indoles and of 2-alkoxycarbonyl-3-anilinoindoles (3) described in this manuscript.   
2. Chemistry 
3-Amino-2-alkoxycarbonyl-1H-indoles 8a-h were synthesized in acceptable yields by 
Thorpe-Zigler cyclization of the corresponding N-aryl glycinate esters 7a-h using t-
BuOK as base in THF. These latter intermediates were prepared starting from 
anthranilonitriles 6a-d by the reaction with the appropriate bromoacetate esters under 
basic medium (NaHCO3). Finally, the novel derivatives 3a-j were prepared using the C-
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N Buchwald-Hartwig palladium catalyzed cross-coupling protocol, by reaction of 3-
amino-1H-indole analogues 8a-h with 1-bromo-3,4,5-trimethoxybenzene or 1-bromo-
3,5-dimethoxybenzene, in the presence of Pd(OAc)2, rac-BINAP and Cs2CO3 (as 
catalyst, ligand and base, respectively) in toluene at 100 °C (Scheme 1).  
 
Scheme 1. Reagents. a: bromoacetate esters, NaHCO3, appropriate solvent, reflux, 24 h; b: t-BuOK, 
THF, rt, 2 h; c: 1-bromo-3,4,5-trimethoxybenzene or 1-bromo-3,5-dimethoxybenzene for the synthesis 
of 3a-h and 3i-j, respectively, Pd(OAc)2, BINAP, Cs2CO3, PhMe, 100 °C, 16 h. 
N-1-alkyl/benzyl indole derivatives 3k-ac were prepared by the synthetic route outlined 
in Scheme 2. The 2-alkoxycarbony-1H-indole derivatives 9a-g were regioselectively 
brominated at the 3-position with N-bromosuccinimide (NBS) in DMF as solvent to 
furnish the corresponding 3-bromo-1H-indole analogues 10a-g in almost quantitative 
yield. The N-1 substituted compounds 11a-p were synthesized in good yields by the 
condensation of N-1H-indole analogues 10a-g with the appropriate alkyl (methyl, ethyl 
or n-propyl) iodide or benzyl bromide using NaH as base in DMF. The subsequent 
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Buchwald-Hartwig reaction of the key building blocks N-alkyl and N-benzyl indole 
derivatives 11a-p with 3,4,5-trimethoxyaniline or 3,5-dimethoxyaniline, following the 
identical protocol reported for the preparation of compounds 3a-j, provided final 
derivatives 3k-ac in acceptable yields.  
 
Scheme 2. Reagents. Reagents. a: NBS, DMF, rt, 2 h; b: appropriate alkyl iodide or benzyl bromide, 
NaH, DMF, rt, 2 h; c: 3,4,5-trimethoxyaniline or 3,5-dimethoxyaniline for the synthesis of 3k-z and 
3aa-ac, respectively, Pd(OAc)2, BINAP, Cs2CO3, PhMe, 100 °C, 16 h. 
3. Biological Results and Discussion 
3.1. In vitro antiproliferative activities.  
The synthesized 2-alkoxycarbonyl-3anilinoindoles 3a-c were evaluated for their ability to 
inhibit the growth of a panel of four human cancer cell lines, cervix carcinoma (HeLa), 
colon adenocarcinoma (HT29), breast adenocarcinoma (MCF-7) and promyelocytic 
leukemia (HL-60) cells. The results are summarized in Table 1, using CA-4 (1a) as the 
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positive control. In general, the human promyelocytic leukemia HL-60 cell line was less 
sensitive to these compounds as compared with the HeLa, HT29 and MCF-7 cells. In 
contrast, the HL-60 cells were more sensitive than the other three lines towards the 
control compound CA-4.  
The data in Table 1 showed that, among the twenty-nine synthesized compounds, the 
most active derivatives (with the exception of 2-ethoxycarbonyl derivative 3q) were 
found among the 2-methoxyxycarbonyl indoles 3h, 3p, 3x and 3y, with antiproliferative 
activity lower than 1 M against all cancer cell lines. Compound 3y, with the N-1-
benzyl-2-methoxycarbonyl-6-methoxy-indole moiety was the most potent compound of 
the series, with antiproliferative IC50 values ranging from 0.055 to 0.17 M against the 
panel of cancer cell lines. Compounds 3h, 3p and 3x had nearly equivalent activity, with 
IC50 values of 0.065-0.49, 0.36-0.77 and 0.063-0.93 M, respectively). In addition, 
derivatives 3a, 3f-g, 3k, 3q, 3s, 3w and 3aa also showed excellent antiproliferative 
activity against the HeLa, HT29 and MCF-7 cancer cell lines, with submicromolar IC50 
values. Half of the synthesized compounds, with IC50 values lower than 1 M against the 
HT29 cell line, were 3-18-fold more potent than CA-4 against this cell line, with 3aa and 
3y as the most active derivatives of the series (IC50:0.17 M), while almost one-third of 
prepared molecules (3g-h, 3m, 3w-y and 3aa) were 2-7-fold more active than CA-4 
against MCF-7 cells (IC50s of 0.055-0.23 M versus 0.37 µM for CA-4). Moreover, all 
synthesized molecules showed substantially reduced activity relative to CA-4 against 
HeLa and HL-60 cancer cells (IC50: 4 and 1 nM, respectively). 
 





Compound HeLa HT29 MCF-7 HL-60 
3a 0.8±0.2 0.47±0.04 0.74±0.54 5.0±1.1 
3b 0.4±0.03 0.74±0.08 1.5±0.6 1.9±0.1 
3c >10 >10 >10 >10 
3d >10 >10 >10 >10 
3e 2.1±0.9 2.0±0.3 0.44±0.02 1.1±0.0 
3f 0.50±0.22 0.96±0.12 0.50±0.38 1.4±1.1 
3g 0.60±0.37 0.48±0.34 0.10±0.09 6.6±3.3 
3h 0.13±0.04 0.47±0.23 0.065±0.054 0.49±0.18 
3i 1.4±0.5 3.7±2.8 0.40±0.01 7.0±1.0 
3j 4.8±4.5 8.7±0.8 1.7±0.2 7.8±1.9 
3k 0.19±0.11 0.60±0.26 0.37±0.32 >10 
3l 1.8±0.1 2.4±1.2 0.74±0.35 >10 
3m 0.62±0.41 1.5±0.5 0.20±0.12 1.6±1.0 
3n 0.53±0.44 1.1±0.6 0.43±0.20 1.7±0.2 
3o 0.60±0.29 1.2±0.5 0.45±0.04 3.2±1.0 
3p 0.68±0.30 0.77±0.13 0.36±0.16 0.60±0.35 
3q 0.60±0.43 0.54±0.30 0.38±0.09 0.68±0.12 
3r 1.3±0.6 1.7±1.3 0.48±0.25 0.64±0.28 
3s 0.95±0.41 0.85±0.15 0.62±0.10 3.0±0.11 
3t 7.8±1.7 5.3±0.8 3.1±2.1 2.6±2.2 
3u >10 >10 >10 >10 
3v >10 >10 >10 >10 
3w 0.54±0.30 0.32±0.03 0.11±0.06 1.1±0.7 
3x 0.58±0.32 0.93±0.18 0.063±0.017 0.10±0.02 
3y 0.13±0.06 0.17±0.02 0.055±0.035 0.096±0.054 
3z 7.3±2.2 1.7±0.1 0.14±0.08 8.1±1.1 
3aa 0.41±0.19 0.17±0.08 0.15±0.04 6.2±1.1 
3ab 0.77±0.00 1.1±0.9 0.3±0.21 6.2±1.0 
3ac 6.3±2.9 6.5±0.2 3.0±2.0 >10 
CA-4 (1a) 0.004±0.001 3.1±0.2 0.37±0,043 0.001±0.0002 
aIC50= compound concentration required to inhibit tumor cell proliferation by 50%. Data are expressed 
as the mean ± SE from the dose-response curves of at least three independent experiments. 
For the derivative 3a, the IC50 values ranged from 0.47 to 0.8 M against three of the 
four cancer cell lines. The elongation of the alkyl chain of 2-alkoxycarbonyl function od 
compound 3a from methyl to ethyl, to yield 3b, has a contrasting effect, with 1.5- and 2-
fold reductions of activity on HT-29 and MCF-7 cells, respectively, and a 2- and 2.5-fold 
increased activity against HeLa and HL-60 cells, respectively. For compounds 3a and 
 11 
3b, replacing a 3,4,5-trimethoxy phenyl ring with a 3,5-dimethoxyphenyl moiety 
(compounds 3i and 3j, respectively) caused a reduction of activity (1.5-12-fold) in all 
cell lines.  
Replacement of methyl or ethyl of the 2-alkoxycarbonyl moiety on the 1H-indole nucleus 
of compounds 3a and 3b with a more bulky t-butyl or benzyl substituent (compounds 3c 
and 3d, respectively) resulted in a dramatic loss of potency (IC50>10 M), thus revealing 
a steric effect of the substituent at the C-2 position of the indole ring on cell growth 
inhibitory activity.  
The introduction of the electron-withdrawing chlorine atom at the C-6 position of the 
1H-indole nucleus of compound 3b, to yield derivative 3e, caused a 3- and 5-fold 
reduction of activity against HT-29 and HeLa cells, respectively, while a 1.5- and 3-fold 
increase of activity was observed against HL-60 and MCF-7 cells. 
The methoxy substituent on the benzene portion of the indole moiety, as well as the 
absence or presence of alkyl or benzyl substituents on the indole nitrogen, play an 
important role in affecting antiproliferative activity. 
The introduction of a methoxy group at the C-5 position of derivative 3a, to yield 3f, 
increased from 1.5 to 3-fold the cell growth inhibitory activity relative to 3a against 
HeLa, MCF-7 and HL-60 cells, with a 1.5-fold reduced activity against HT29 cells. 
Homologation of the alkyl chain of the alkoxycarbonyl group by an extra methylene unit, 
from methyl to ethyl (compounds 3f and 3g, respectively), increased antiproliferative 
activity 2- and 5-fold against HT-29 and MCF-7 cells, respectively, while the 2-
ethoxycarbonyl-1H-indole derivative 3g was 5-fold less potent than 3f against HL-60 
cells, and the two derivatives proved equipotent against HeLa cells. For compound 3f, 
 12 
moving the methoxy group from the 5-to the 6-position of the 1-H-indole ring 
(derivative 3h) increased activity 2-8-fold against the whole panel of cancer cell lines.   
Through the synthesis of compounds 3k-ac, we investigated whether the introduction of 
a methyl, ethyl, n-propyl or benzyl moiety at the indole nitrogen of derivatives 3f-h 
would lead to an increase or loss of activity through a steric effect. Starting from 
compound 3f, the insertion of a methyl group at the N-1 position of the indole nucleus 
(3m) caused a 2.5-fold increase in antiproliferative activity relative to 3f against MCF-7 
cells, while the two derivatives were equipotent against the other cancer cell lines. 
Replacement of the C-5 methoxy of 3m with a weak electron-releasing methyl group 
(3k), increased potency 2.5 and 3-fold against HT-29 and HeLa cells, respectively, while 
a strong reduction in activity (27-fold) was observed against HL-60 cells. For compound 
3m, replacement of the 3,4,5-trimethoxyphenyl ring with a 3,5-dimethoxy phenyl moiety 
(3aa) was well tolerated by the HeLa and MCF-7 cells, with the two compounds 
showing similar potency, while the latter compound was 9-fold more active than the 
former against HT-29 cells. In contrast, 3m was 4-fold more potent than 3aa against the 
HL-60 cell line.  
Homologation of the N-1 alkyl chain on the indole nucleus from methyl to ethyl to n-
propyl (compounds 3m, 3n and 3o, respectively), maintained antiproliferative activity 
relative to the N-methyl derivative 3m on the HeLa and HT-29 cell lines, while 3n and 
3o were equipotent although half as potent as the N-1H-indole derivative 3m against 
MCF-7 cells. The n-propyl derivative 3o was half as active as 3m and 3n against HL-60 
cells, with these latter derivatives being equipotent.  
For the 2-methoxycarbonyl indole derivative 3m, the N-1-methyl can be replaced with a 
benzyl moiety (compound 3p) without substantial loss of activity against HeLa cells, and 
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with a 2-fold increase in potency against HT-29 and HL-60 cells, while antiproliferative 
activity was reduced 2-fold against MCF-7 cells. Replacement of the C-6 methoxy of 
derivative 3p with a methyl (3l) caused a reduction of antiproliferative activity relative to 
3p, which was moderate (2-3-fold) against three of the four cancer cell lines, and 
dramatic (85-fold) on HL-60 cells.   
For the 2-ethoxycarbonyl-1H-indole derivative 3g, replacement of hydrogen with a 
methyl group at the indolic nitrogen, to furnish derivative 3q, maintained potency against 
HeLa and HT-29 cells relative to 3g, while an opposite effect was observed against the 
other two cancer cell lines, with a 4-fold reduction of potency against MCF-7 cells and a 
10-fold increase of activity against HL-60 cells.  
The 3’,4’,5’-trimethoxyanilino moiety of compound 3q can be replaced with a 3,5-
dimethoxyanilino function (3ab) without loss of activity against HeLa and MCF-7 cells, 
while 3ab was 2- and 9-fold less active than 3q against HT-29 and HL-60 cells, 
respectively. The substitution of the N-1-methyl group of 3q with a bulkier benzyl 
moiety (3r) was tolerated against MCF-7 and HL-60 cells, while a 2- and 3-fold 
reduction in activity was observed against HeLa and HT-29 cells, respectively.  
Comparing the activities of derivatives characterized by the presence of a common N-1-
methyl-5-methoxy indole nucleus and a different 2-alkoxycarbonyl function (3m, 3q, 3s 
and 3u), the 2-methoxycarbonyl derivative 3m had 2- and 3-fold reduced activity relative 
to the corresponding 2-ethoxycarbonyl homologue 3q against HL-60 and HT-29 cells, 
while this latter compound was 2-fold less potent than 3m against MCF-7 cells. The two 
derivatives showed similar potency against Hela cells. A further homologation of the 
alkyl chain of the alkoxycarbonyl moiety from ethyl to n-propyl (3s) slightly decreased 
antiproliferative activity. Reduction of activity was dramatic (two-orders of magnitude) 
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when the n-propyl chain of 2-alkoxycarbonyl derivative 3s was replaced with the 
isomeric, branched isopropyl group, to yield the isopropyl ester 3u. A reduction of 
potency (5-10-fold) was also observed by replacing the 3,4,5-trimethoxyphenyl ring of 
3s with a 3,5-dimethoxyphenyl system (3ac). Replacement of the N-1-methyl group of n-
propyloxycarbonyl indole derivative 3s with a more bulky and lipophilic benzyl group 
(3t) also had a pronounced effect on potency, with a reduction n activity on three of the 
cell lines, while the two compounds were equipotent against HeLa cells.  
For 2-methoxycarbonyl indole derivatives 3f, 3h, 3m, 3p and 3w-z, the position of the 
methoxy group on the benzene portion of the indole moiety was crucial for 
antiproliferative activity, with the greatest potency occurring when the methoxy group 
was located at the C-6 position. 
Comparing the activities of the three isomeric N-1-methyl-2-methoxycarbonyl indole 
derivatives 3m, 3w and 3z, the greatest activity occurred when the methoxy group was 
located at the C-6 position (3w), the least when it was located at the C-7 position (3z). 
A contrasting effect was observed comparing the activities of the N-1-methyl/ethyl-6-
methoxy-2-methoxycarbonyl pair 3w and 3x, with the N-1-methyl derivative 3w being 2- 
and 10-fold less active than its N-1-ethyl homologue 3x against MCF-7 and HL-60 cells, 
respectively, while the two compounds were equipotent against HeLa cells. Only against 
the HT-29 cells, 3x was 3-fold more active than 3w.  
For the C-6 methoxy derivative 3x, replacement of the N-1-ethyl with a benzyl group 
(3y) maintained antiproliferative activity against MCF-7 and HL-60 cells, with the latter 
derivative being 4- and 5- fold more active than the former against Hela and HT-29 cells, 
respectively.  
3.2. In vitro inhibition of tubulin polymerization and colchicine binding. 
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As presented in Table 1, nine compounds, 3f-g, 3k, 3m, 3o-p, 3w, 3y and 3aa, as well as 
reference compound CA-4, were evaluated for their antitubulin polymerization activities 
in order to understand whether these new 2-alkoxycarbonyl indoles exerted their 
antiproliferative activities through an interaction with microtubules. The selected 
compounds were also examined at two different concentrations (5 and 0.5 M) for their 
ability to compete with colchicine for binding to tubulin using a [3H]colchicine binding 
assay.  
In the tubulin polymerization assay, seven out of nine of the tested compounds (3f-g, 3k, 
3m, 3aa, 3w and 3y) strongly inhibited tubulin assembly with activities comparable or 
slightly superior (IC50: 0.37-0.68 M) to that of CA-4 (IC50: 0.54 M), while derivative 
3o (IC50:1.6 M) was 3-fold less active than CA-4. Despite appreciable cell growth 
inhibitory activity (IC50: 0.36-0.77 M) against the panel of cancer cells, compound 3p 
was inactive in the tubulin polymerization assay (IC50>20 M), indicating that this 
molecule may exert its antiproliferative effect by a different mechanism of action. When 
comparing the inhibition of tubulin polymerization versus the growth inhibitory effect, 
we found that the potency of these seven molecules for inhibition of tubulin assembly 
was comparable with the activity observed for CA-4, but they were considerably less 
active than CA-4 as antiproliferative agents against HeLa and HL-60 cells. This 
discrepancy can possibly be rationalized by a limited penetration into the cells or any 
other mechanism limiting the accessibility of these molecules to cellular tubulin. 
Table 2. Inhibition of tubulin polymerization and cochicine binding by compounds 3f-g, 








 5 M drug 0.5 M drug 
3f 0.40±0.07 94±0.6 53±0.04 
3g 0.84±0.1 80±2 n.d. 
3k 0.53±0.04 67±5 n.d. 
3m 0.54±0.03 75±2 n.d. 
3o 1.6±0.2 44±1 n.d. 
3p >20 15±0.6 n.d. 
3w 0.37±0.07 97±2 75±4 
3y 0.42±0.07 68±0.9 n.d. 
3aa 0.47±0.03 82±1 n.d. 
CA-4 (1a) 0.54±0.06 98±0.9 85±2 
a Inhibition of tubulin polymerization. Tubulin was at 10 M. 
b Inhibition of [3H]colchicine binding. Tubulin and colchicine were at 0.5 and 5 M concentrations, 
respectively. 
n.d.=not determined 
In the colchicine competition experiments, compounds 3f-g, 3m, 3w and 3aa at 5 M 
strongly inhibited [3H]colchicine binding to tubulin, with 68-97% of inhibition. 
Compounds 3f and 3w were the most potent inhibitors of tubulin polymerization 
(IC50=0.40 and 0.37 M, respectively), and this was also confirmed in the colchicine 
binding assay (94% and 97% inhibition at 5 µM). When the concentration of 3f and 3w 
was 0.5 M, 53% and 75% inhibition, respectively, of the binding of [3H]colchicine to 
tubulin was observed. In addition, compounds 3f and 3w were as active as CA-4 as 
inhibitors of colchicine binding at 5 M, while the difference between 3f and CA-4 was 
more prominent than that between 3w and CA-4 at 0.5 M.  
Comparing the activities of compounds 3m and 3aa, we can observe that the 3’,4’,5’-
trimethoxyphenyl moiety of 3m, a well-defined pharmacophore for the inhibition of 
tubulin polymerization found in colchicine, CA-4 and podophyllotoxin, was not essential 
 17 
for potent inhibition of tubulin polymerization and colchicine binding. This moiety can be 
replaced with the 3’,5’-dimethoxyphenyl ring of derivative 3aa without loss of activity 
(IC50=0.54 and 0.47 M for assembly, 75% and 82% inhibition of the binding of 
colchicine for 3m and 3aa, respectively, at 5 M). A linear correlation between 
inhibition of tubulin assembly and colchicine binding inhibition was observed between 
analogue pairs 3m/3aa and 3f/3w, while a different behaviour was observed for 
derivatives 3w and 3y. These latter compounds were both equipotent as inhibitors of 
tubulin assembly, while 3w was much more active than 3y as an inhibitor of 
[3H]colchicine binding (97% and 68% inhibition, respectively).  
3.3. Molecular modeling studies. 
The tubulin colchicine binding site is a flexible area, which can adapt to different ligands 
by changing the architecture of the pocket. Diverse ligands may induce different 
conformations of the same protein, and therefore an inhibitor, whose structure induces a 
specific protein conformation, may not be correctly docked by the program against 
another protein conformation, often giving poor correlation between biological data and 
computational results. In order to explore the potential binding mode of selected newly 
synthesized compounds (3f, 3g, 3k, 3m, 3o, 3p, 3w, 3y and 3aa) and to consider the 
flexibility of the colchicine binding domain, an ensemble docking study using Glide SP 
was performed [40]. Ensemble docking reduces potential evaluation errors associated 
with receptor rigidity by docking a series of ligands against multiple crystal structures of 
the same protein.  
Three crystal structures were used: tubulin co-crystallized with vinblastine (PDB ID: 
5BMV) [41], in which the colchicine binding domain is unoccupied; tubulin co-
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crystallized with colchicine (PDB ID: 4O2B) [42]; and tubulin co-crystallized with 
microtubule-destabilizing CA-4 (1a) (PDB ID: 5LYJ) [43]. These crystals represent 
three different conformations of the colchicine binding area.  
While, as expected, none of the molecules was docked by Glide in the unbound form of 
tubulin (5BMV), the CA-4-tubulin complex (5LYJ) was able to correctly accommodate 
only compound 3f and 3g, the unsubstituted derivatives at the N-1 position, whereas the 
rest of the molecules either provided an implausible binding mode if correlated with their 
biological activity (3k, 3m, 3o and 3aa), or were not docked by the program (3p, 3w, 
and 3y). Interestingly, these compounds are all characterised by various substitutions at 
the N-1 position of the indole ring. In contrast, all the compounds were correctly docked 
in the colchicine-tubulin crystal structure (4O2B). The loop formed by residues between 
Gln247 and Ala250 occupies the central area of the colchicine domain on the 
unoccupied tubulin structure, not allowing the binding of any ligand (Figure 2). The 
presence of colchicine or CA-4 forces this loop to move away from this area, inducing 
the formation of the binding pocket. A second loop, which goes from Ser178 to 
Val181, further reduces the size of the colchicine domain by moving toward the -
tubulin unit in both crystal structures, the unbound form (5BMV) and the CA-4-tubulin 
complex (5LYJ), whereas the lateral amide substituent of colchicine pushes this loop to 
widen the binding area (4O2B) (Figure 2).  
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Figure 2. Superposition of the colchicine binding site of three tubulin crystal structures: unoccupied 
colchicine binding domain (PDB ID: 5BMV. The -tubulin unit is represented as a light green ribbon; 
the -tubulin unit is represented as a dark green ribbon); tubulin co-crystallized with colchicine (PDB 
ID: 4O2B. The -tubulin unit is represented as an air force blue ribbon; the -tubulin unit is represented 
as a dark blue ribbon. Co-crystallized colchicine is shown in blue); tubulin co-crystallized with 
microtubule-destabilizing CA-4 (PDB ID: 5LYJ. The -tubulin unit is represented as a pink ribbon; the 
-tubulin unit is represented as a salmon ribbon. Co-crystallized CA-4 is shown in pink). The Gln247-
Ala250 loop is represented in red, whereas the Ser178-Val181 loop in represented in yellow. Note 
the different architecture of the colchicine binding area in the three crystal structures.  
3f and 3g, the two compounds that obtained the best docking score in both crystals, 
occupy the active site similarly to the co-crystallized ligands, with the trimethoxyphenyl 
ring overlapping the same ring in the CA-4 and colchicine structures (Figure 3).  
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Figure 3. Proposed binding mode for compound 3f in 5LYJ (A) and 4O2B (B) and for compound 3g in 
5LYJ (C) and 4O2B (D). The two compounds occupy the active site similarly to the co-crystallized 
ligands, especially their trimethoxyphenyl rings. Co-crystallized CA-4 is shown in pink, colchicine in 
blue, compound 3f in yellow and compound 3g in dark purple. The -tubulin unit from 5LYJ is 
represented as a pink ribbon, and the -tubulin unit is shown as a salmon ribbon. The -tubulin unit 
form 4O2B is represented as a blue ribbon, and the -tubulin unit is represented as a dark blue ribbon. 
The Gln247-Ala250 loop is represented in red, and the Ser178-Val181 loop in represented in 
yellow.  
The anilinic nitrogen bridging the indole nucleus and the 3’,4’,5’-trimethoxyphenyl 
confers a conformation to the molecules that mimics the CA-4 cis-olefin bridge and the 
central colchicine B ring. H-bond formation between the 4-methoxy group and Cys241 
is present in both crystals, while interaction between the indole NH and Thr179 and 
between the carboxylic group and Ala250/Asn268 further stabilize the compounds on 
the CA-4 binding site. As mentioned above, introduction of various substitutions at the 
N-1 position of the indole ring does not allow a correct occupation of the binding area 
on the CA-4-tubulin complex (5LYJ), potentially due to steric clashes between the 
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different substituents and the Ser178-Val18 loop. Analyzing the docking results on 
the colchicine-tubulin crystal structure (4O2B), the simultaneous presence of the 
methoxy group at the 5-position and a substituent at the N-1 of the indole nucleus forces 
the compounds to occupy the active site in a non-optimal manner, potentially resulting in 
a reduced inhibition of colchicine binding (Figure 4). In particular, the anilinic nitrogen 
bridge assumes a conformation that impedes the central indole core from overlapping the 
central colchicine B ring, and this effect is accentuated with increasing N-1 substituent 
size. 3p, with a benzyl substituent at N-1, did not have a plausible binding mode, in 
agreement with its low ability to inhibit colchicine binding (Figure 4).  
 
Figure 4. Proposed binding modes for compound 3m in 5LYJ (A) and 4O2B (B) and for compound 3p 
in 4O2B (C). Introduction of a methyl group at the N-1 position of the indole ring does not allow correct 
occupation of the binding area on the CA-4-tubulin complex (5LYJ) by 3m (A), potentially due to steric 
clashes between the methyl group and the Ser178-Val181 loop. Although compound 3m is able to 
bind to the colchicine-tubulin crystal structure (4O2B), the simultaneous presence of the methoxy group 
at the 5-position and a substituent at the N-1 of the indole nucleus forces the compound to sit in the 
active site in a non-optimal manner (A). In particular, the anilinic nitrogen bridge assumes a 
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conformation that impedes the central indole core of 3m from superimposing on ring B of colchicine. 
Compound 3p, having a benzyl substituent on N-1, did not show a plausible binding mode on 4O2B, 
which is consistent with its minimal inhibition of colchicine binding. Co-crystallized CA-4 is shown in 
pink, colchicine in blue, compound 3m in green and compound 3p in gold. The -tubulin unit from 
5LYJ is represented as a pink ribbon, and the -tubulin unit is shown as a salmon ribbon. The -tubulin 
unit from 4O2B is represented as a blue ribbon, and the -tubulin unit is represented as a dark blue 
ribbon. The Gln247-Ala250 loop is represented in red, and the Ser178-Val181 loop in represented 
in yellow.  
Moving the methoxy group from position 5 to 6 (3w) allows a correct occupation of the 
binding area, comparable to the binding pose found for 3f, and is in accord with the 
colchicine binding assay results (Figure 5). Increasing the size of the N-1 substituent to a 
benzyl ring (3y) causes a change in the anilinic nitrogen bridge similar to the one 
observed for 3m, potentially explaining the similar inhibition of colchicine binding found 
for these three compounds (Figure 5). Finally, the 3’,5’-dimethoxyphenyl compound 
3aa binds in the active site similarly to the 3’,4’,5’-trimethoxyphenyl derivative 3m, in 
accord with their similar inhibition of colchicine binding. 
 
Figure 5. Proposed binding mode for compounds 3w (A) and 3y (B) in 4O2B. Moving the methoxy 
group from position 5 to 6 in 3w allows a correct occupation of the binding area despite the presence of 
a methyl group at the N-1 position (A). Increasing the size of the N-1 substituent to a benzyl ring in 3y 
causes a change in the anilinic nitrogen bridge similar to the one observed for 3m. Co-crystallized 
colchicine is shown in blue, compound 3y in salmon and compound 3y in orange. The -tubulin unit 
from 4O2B is represented as a blue ribbon, and the -tubulin unit is represented as a dark blue ribbon. 
The Gln247-Ala250 loop is represented in red, and the Ser178-Val181 loop in represented in 
yellow.   
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In conclusion, molecular docking studies have given important insights on the potential 
binding mode for this family of compounds. Furthermore, the results have highlighted the 
importance of selecting the appropriate crystal structure of a given protein to perform 
reliable docking simulations. 
3.4. Analysis of cell cycle effects.  
Since molecules exhibiting activity on tubulin binding should cause alteration of cell 
cycle parameters, leading to a preferential G2/M blockade, the effects of compounds 3m, 
3w and 3y on cell cycle distribution were analyzed on HeLa cells cultured for 24 h in the 
presence of. six different concentrations ranging from 6.4x10-4 to 2 µM for each tested 
derivative (Table 3). All three compounds caused a dose-dependent accumulation of 
cells in the G2/M phase, with a concomitant reduction of cells in the G1 phase. 
Compound 3w was the most active compound since at 0.0032 μM it induced a 
significant increase in cells in the G2/M phase (Figure 6), in excellent agreement with the 
data on inhibition of tubulin polymerization. The other two compounds (3m and 3y) 

















Distribution of cells (%)
a 
Sub-G1 G0/G1 S G2/M 
3m 2 9.95±4.11 12.22±4.34 12.01±4.39 65.82±4.57 
 0.4 11.62±1.31 16.46±2.91 16.50±4.69 55.42±8.79 
 0.08 6.18±1.44 25.94±2.39 37.23±6.27 30.66±9.54 
 0.016 1.75±1.23 58.74±11.27 16.90±1.17 22.60±8.88 
 0.0032 2.78±2.99 65.21±3.57 17.68±0.41 14.33±5.31 
 0.00064 4.19±2.90 61.99±1.65 19.59±2.28 14.22±4.03 
 0 3.22±3.45 61.93±4.18 14.59±2.02 18.99±3.83 
3w 2 7.99±5.49 8.74±1.33 11.46±1.18 71.80±4.83 
 0.4 7.21±2.26 12.87±5.06 14.13±5.06 65.80±5.25 
 0.08 5.99±2.14 10.57±2.52 13.80±1.69 69.66±1.94 
 0.016 5.59±3.30 10.23±2.78 13.63±4.68 70.55±10.62 
 0.0032 6.76±1.61 14.93±3.14 33.04±4.12 45.27±3.77 
 0.00064 3.14±2.17 67.28±4.13 15.60±3.80 13.98±2.04 
 0 3.22±3.45 61.93±4.18 14.59±2.02 18.99±3.83 
3y 2 7.97±2.47 10.42±5.67 11.01±2.81 70.61±5.64 
 0.4 9.33±2.45 11.51±3.82 12.42±2.62 66.75±4.77 
 0.08 4.46±0.45 52.79±3.93 18.69±1.67 24.05±3.13 
 0.016 3.60±2.34 67.42±4.08 20.77±4.73 8.21±5.60 
 0.0032 11.12±12.37 59.46±10.66 21.89±0.89 7.54±3.03 
 0.00064 13.78±13.85 60.32±12.40 20.71±5.26 5.19±1.39 
 0 3.22±3.45 61.93±4.18 14.59±2.02 18.99±3.83 
CA-4 (1a) 2 14.75±6.47 8.45±4.23 7.74±0.54 69.07±4.36 
 0.4 8.13±3.97 10.55±3.80 14.32±2.86 66.99±4.98 
 0.08 6.78±2.80 10.10±2.49 15.19±1.83 67.92±6.91 
 0.016 9.32±1.12 14.31±2.87 15.24±3.07 61.13±1.31 
 0.0032 13.63±4.85 13.90±4.10 15.43±0.93 57.02±9.27 
 0.00064 10.50±2.60 33.98±11.03 23.41±10.42 32.11±1.54 
 0 3.22±3.45 61.93±4.18 14.59±2.02 18.99±3.83 
a Percentages of cells in each phase of the cell cycle in HeLa cells treated with the indicated compounds 
at the indicated concentrations for 24 h. CA-4 (1a) was used as a positive control. Cells were fixed and 
labeled with DAPI and analyzed by high content imaging as described in the experimental section. Data 






Figure 6. The impact of compounds 3m, 3w and 3y on cell cycle of HeLa cells. HeLa cells were treated 
with six different concentrations of 3m, 3w, 3y and reference compound CA-4 (1a) for 24 h and then 
assayed via high content imaging. The bar chart shows the percentage of cell cycle distribution based on 
the imaging results. 
3.5. Apoptosis induction assay of compounds 3m, 3w and 3y in HeLa cancer and 
human non-cancer cells.  
To determine the ability of compounds 3m, 3w and 3y to induce apoptosis, HeLa and 
healthy human peripheral blood mononuclear cells (PBMC) were incubated and 
monitored at 37 °C for three days in the presence of each compound at different 
concentrations ranging from 6.4x10-4 to 10 µM. The induction of apoptosis was 
monitored by the activation of caspase 3/7, a well-known marker of apoptosis, using a 
commercial kit, as described in the experimental procedures. CA-4 was employed as a 
control compound. As shown in Table 4, derivatives 3m, 3w and 3y, as well as CA-4, 
were ineffective in PBMC, with IC50 values (>10 M) that were negligible as compared 
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with those found against the HeLa cancer cells and against other cancer cell lines (Table 
1). Altogether, these data suggest that these compounds not only induce apoptosis but 
may also have cancer cell selective antiproliferative properties. 
Table 4. EC50 values for apoptosis induction by 3m, 3w, 3y and control compound CA-
4 (1a) in HeLa cancer cells and PBMC. 
 EC50
a (M) caspase 3/7 activation 
Compound HeLa PBMC 
3m 0.37±0.11 >10 
3w 0.069±0.008 >10 
3y 0.53±0.16 >10 
CA-4 (1a) 0.005±0.002 >10 
aEC50= compound concentration required to inhibit cell viability by 50% through activation of caspase 




In this report we have demonstrated that replacing the sulfur atom, carbonyl moiety or 
methylene unit bridging the 3’,4’,5’-trimethoxyphenyl ring and C-3 position of the indole 
nucleus of compounds with general structure 2 previously reported by Silvestri et al. 
with an anilinic nitrogen (NH) yielded a new series of 2-alkoxycarbonyl-3-anilino indoles 
with general formula 3 with potent antiproliferative activity caused by their inhibition of 
tubulin polymerization. Various substituents were tolerated on the indolic nitrogen, with 
alkyl and benzyl substitution of compounds 3k-ac that generally led to little effect on 
antiproliferative potency, while a small-sized methoxy/ethoxycarbonyl moiety at the 2-
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position of the indole nucleus is important for optimal antiproliferative activity (as 
depicted in Figure 6). The 3’,4’,5’-trimethoxyanilino moiety at the 3-position of the 
indole skeleton can be replaced by a 3’,5’-dimethoxyanilino function without a loss of 
activity (compare 3a with 3i, 3b with 3j, 3m with 3aa and 3q with 3ab). Further 
analysis of the SAR showed that antiproliferative activity is also related to the presence 
and position of the methoxy group at the C-5 or C-6 position on the benzene portion of 
the indole ring, with the 6-OMe derivatives generally more active than their 
corresponding 5-OMe counterparts (i.e, 3g vs. 3h, 3m vs. 3w, 3n vs. 3x, 3p vs. 3y).  
The data identified tubulin as the molecular target of most compounds, since those with 
the greatest inhibitory effects on cell growth strongly inhibited tubulin assembly and the 
binding of colchicine to tubulin, with a good correlation between the inhibition of tubulin 
polymerization versus the antiproliferative effects. In particular we have identified 2-
methoxycarbonyl-3-(3’,4’.5’-trimethoxyanilino)-5-methoxyindole (3f) and 1-methyl-2-
methoxycarbonyl-3-(3’,4’,5’-trimethoxyanilino)-6-methoxyindole (3w) as new 
antiproliferative agents that target tubulin at the colchicine site with antitubulin activities 
comparable to that of the reference compound CA-4. 
Three of the most active compounds in the tubulin assay, corresponding to 2-
methoxycarbonyl-3-(3’,4’.5’-trimethoxyanilino) indoles 3w, 3m and 3y, induced arrest 
of Hela cells in the G2/M phase of the cell cycle. Further experiments demonstrated that 
these compounds induce apoptosis in Hela cells and were practically devoid of significant 





Figure 7. SAR analysis of 2-alkoxycarbonyl-3-anilino indole analogues 3a-c  
5. Experimental Protocols. 
5.1. Chemistry.  
5.1.1. Materials and Methods.  
1H experiments were recorded on either a Bruker AC 200 or a Varian 400 Mercury Plus 
spectrometer, while 13C NMR spectra were recorded on a Varian 400 Mercury Plus 
spectrometer. Chemical shifts () are given in ppm upfield from tetramethylsilane as 
internal standard, and the spectra were recorded in appropriate deuterated solvents, as 
indicated. Positive-ion electrospray ionization (ESI) mass spectra were recorded on a 
double-focusing Finnigan MAT 95 instrument with BE geometry. Melting points (mp) 
were determined on a Buchi-Tottoli apparatus and are uncorrected. Microwave-assisted 
reactions were performed on a CEM Discover SP single-mode reactor. Closed vessel 
experiments were carried out in capped microwave-dedicated vials (10 mL). The 
temperature of the reaction was monitored by an external fiber optic temperature sensor. 
After completion of the reaction, the mixture was cooled to 25 °C via air-jet cooling. All 
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products reported showed 1H and 13C NMR spectra in agreement with the assigned 
structures. The purity of tested compounds was determined by combustion elemental 
analyses conducted by the Microanalytical Laboratory of the Chemistry Department of 
the University of Ferrara with a Yanagimoto MT-5 CHN recorder elemental analyzer. 
All tested compounds yielded data consistent with a purity of at least 95% as compared 
with the theoretical values. All reactions were carried out under an inert atmosphere of 
dry nitrogen, unless otherwise indicated. Standard syringe techniques were used for 
transferring dry solvents. Reaction courses and product mixtures were routinely 
monitored by TLC on silica gel (precoated F254 Merck plates), and compounds were 
visualized with aqueous KMnO4. Flash chromatography was performed using 230-400 
mesh silica gel and the indicated solvent system. Organic solutions were dried over 
anhydrous Na2SO4. 
5.1.2. General method A for the synthesis of compounds 7a-h.   
A suspension of the appropriate 2-aminobenzonitrile 6a-d (10 mmol), appropriate alkyl 
or benzyl bromoacetate (10 mmol) and NaHCO3 (0.99 g, 12 mmol, 1.2 equiv.) in the 
appropriate solvent (10 mL) was stirred at reflux for 24 h. After this time, the 
appropriate alkyl or benzyl bromoacetate (10 mmol) was added and the mixture heated 
at reflux for an additional 24 h. The reaction mixture was cooled to ambient temperature 
and filtered through Celite, then the filtrate was evaporated in vacuo. The residue was 
diluted with dichloromethane (25 mL) and washed sequentially with water (10 mL) and 
brine (10 mL). The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure, and the residue was stirred with the appropriate solvent or purified by 
flash column chromatography on silica gel.  
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5.1.2.1. Methyl 2-[(2-cyanophenyl)amino]acetate (7a). Following general procedure A, 
the product was synthesized using 2-aminobenzonitrile 6a, methyl bromoacetate and 
MeOH as solvent. The crude residue was suspended in EtOH and filtered to furnish 7a 
as a yellow solid. Yield: 54%, mp 86 °C. 1H-NMR (CDCl3) : 3.80 (s, 3H), 3.99 (d, 
J=5.4 Hz, 2H), 5.12 (bs, 1H), 6.53 (d, J=8.4 Hz, 1H), 6.75 (t, J=8.4 Hz, 1H), 7.42 (m, 
2H). MS (ESI): [M]+=190.5.  
5.1.2.2. Ethyl 2-[(2-cyanophenyl)amino]acetate (7b). Following general procedure A, 
the product was synthesized using 2-aminobenzonitrile 6a, ethyl bromoacetate and EtOH 
as solvent. The crude residue was suspended in petroleum ether and filtered to furnish 7b 
as a yellow solid. Yield: 83%, mp 90 °C. 1H-NMR (CDCl3) : 1.30 (t, J=7.2 Hz, 3H), 
3.97 (d, J=5.4 Hz, 2H), 4.25 (q, J=7.2 Hz, 2H), 5.22 (bs, 1H), 6.53 (d, J=8.2 Hz, 1H), 
6.74 (t, J=8.2 Hz, 1H), 7.41 (m, 2H). MS (ESI): [M+1]+=205.3.  
5.1.2.3. tert-butyl 2-[(2-cyanophenyl)amino]acetate (7c). Following general procedure 
A, the product was synthesized using 2-aminobenzonitrile 6a, tert-butyl bromoacetate 
and tert-butanol as solvent. The crude residue was purified by flash chromatography, 
using ethyl acetate:petroleum ether 1:9 (v:v) as eluent, to furnish 7c as a yellow oil. 
Yield: 52%. 1H-NMR (CDCl3) : 1.48 (s, 9H), 3.88 (d, J=5.0 Hz, 2H), 5.21 (bs, 1H), 
6.51 (d, J=8.2 Hz, 1H), 6.73 (t, J=8.2 Hz, 1H), 7.40 (m, 2H). MS (ESI): [M]+=233.3.  
5.1.2.4. Benzyl 2-[(2-cyanophenyl)amino]acetate (7d). Following general procedure A, 
the product was synthesized using 2-aminobenzonitrile 6a, benzyl bromoacetate and 
acetonitrile as solvent. The crude residue was purified by flash chromatography, using 
ethyl acetate:petroleum ether 1:9 (v:v) as eluent, to furnish 7d as a white solid. Yield: 
77%, mp 92 °C. 1H-NMR (CDCl3) : 4.02 (d, J=5.6 Hz, 2H), 5.12 (bs, 1H), 5.23 (s, 
 31 
2H), 6.50 (d, J=8.4 Hz, 1H), 6.74 (t, J=8.4 Hz, 1H), 7.36 (m, 7H). MS (ESI): 
[M]+=266.3.  
5.1.2.5. Ethyl 2-[(5-chloro-2-cyanophenyl)amino]acetate (7e). Following general 
procedure A, the product was synthesized using 4-chloro-2-aminobenzonitrile 6b, ethyl 
bromoacetate and DMF as solvent. The crude residue was purified by flash 
chromatography, using ethyl acetate:petroleum ether 1:9 (v:v) as eluent, to furnish 7e as 
a white solid. Yield: 77%, mp 132 °C. 1H-NMR (CDCl3) : 1.34 (t, J=7.0 Hz, 3H), 3.94 
(d, J=5.4 Hz, 2H), 4.26 (q, J=7.2 Hz, 2H), 5.20 (bs, 1H), 7.07 (dd, J=8.2 and 2.0 Hz, 
1H), 7.45 (d, J=8.2 Hz, 1H), 8.36 (d, J=2.0 Hz, 1H). MS (ESI): [M+1]+=239.7.4. 
5.1.2.6. Methyl 2-[(2-cyano-4-methoxyphenyl)amino]acetate (7f). Following general 
procedure A, the product was synthesized using 5-methoxy-2-aminobenzonitrile 6c, 
methyl bromoacetate and CH3CN as solvent. The crude residue was purified by flash 
chromatography, using ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 7f as 
a white solid. Yield: 58%, mp 132 °C. 1H-NMR (CDCl3) : 3.89 (m, 5H), 4.08 (s, 3H), 
5.16 (bs, 2H), 6.62 (dd, J=9.0 and 2.2 Hz, 1H), 7.53 (d, J=9.0 Hz, 1H), 7.93 (d, J=2.2 
Hz, 1H). MS (ESI): [M]+=221.4. 
5.1.2.7. Ethyl 2-[(2-cyano-4-methoxyphenyl)amino]acetate (7g). Following general 
procedure A, the product was synthesized using 5-methoxy-2-aminobenzonitrile 6c, 
ethyl bromoacetate and CH3CN as solvent. The crude residue was purified by flash 
chromatography, using ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 7g as 
a white solid. Yield: 56%, mp 124 °C. 1H-NMR (CDCl3) : 1.34 (t, J=7.2 Hz, 3H), 3.88 
(d, J=5.2 Hz, 2H), 3.96 (s, 3H), 4.24 (q, J=7.2 Hz, 2H), 5.22 (bs, 1H), 6.59 (dd, J=9.0 
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and 2.4 Hz, 1H), 7.18 (bs, 1H), 7.41 (d, J=9.0 Hz, 1H), 7.87 (d, J=2.4 Hz, 1H). MS 
(ESI): [M]+=235.2.  
5.1.2.8. Methyl 2-[(2-cyano-5-methoxyphenyl)amino]acetate (7h). Following general 
procedure A, the product was synthesized using 4-methoxy-2-aminobenzonitrile 6d, 
methyl bromoacetate and CH3CN as solvent. The crude residue was purified by flash 
chromatography, using ethyl acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 7h as 
a white solid. Yield: 58%, mp 132 °C. 3.89 (m, 5H), 4.10 (s, 3H), 5.06 (bs, 1H), 6.59 
(dd, J=8.8 and 2.4 Hz, 1H), 7.18 (bs, 1H), 7.41 (d, J=8.8 Hz, 1H), 7.87 (d, J=2.4 Hz, 
1H). MS (ESI): [M]+=221.4  
5.1.3. General method B for the preparation of compounds 8a-h.  
Potassium tert-butoxide (0.56 g, 5 mmol) was dissolved in dry THF (5 mL). The mixture 
was cooled in a bath of ice and water, and the appropriate alkyl/benzyl 2-((2-
cyanophenyl)amino)acetate 7a-h (5 mmol) dissolved in THF (5 mL) was added 
dropwise. The reaction mixture was allowed to warm to room temperature, stirred for 2 
h and diluted with water (10 mL). The mixture was extracted with EtOAc (20 mL) and 
the organic layer washed with a water and brine solution. The EtOAc layer was dried 
over Na2SO4 and evaporated to obtain a residue purified by flash column 
chromatography on silica gel. For the characterization of methyl 3-amino-1H-indole-2-
carboxylate (8a), ethyl 3-amino-1H-indole-2-carboxylate (8b) and tert-butyl-3-amino-
1H-indole-2-carboxylate (8c), see reference [44]. For the characterization of ethyl 3-
amino-5-methoxy-1H-indole-2-carboxylate (8g) and methyl 3-amino-6-methoxy-1H-
indole-2-carboxylate (8h), see references [45] and [46], respectively.  
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5.1.3.1. Benzyl 3-amino-1H-indole-2-carboxylate (8d). Following general procedure B, 
the crude residue was purified by flash chromatography, using ethyl acetate:petroleum 
ether 3:7 (v:v) as eluent, to furnish 8d as an eggshell solid. Yield: 54%, mp 112 °C. 1H-
NMR (CDCl3) : 4.72 (bs, 2H), 5.37 (s, 2H), 7.12 (m, 1H), 7.37 (m, 7H), 7.56 (d, J=7.2 
Hz, 1H), 7.82 (bs, 1H). MS (ESI): [M]+=267.3.  
5.1.3.2. Ethyl 3-amino-6-chloro-1H-indole-2-carboxylate (8e). Following general 
procedure B, the crude residue was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 8e as a brown solid. Yield: 65%, 
mp 168 °C. 1H-NMR (CDCl3) : 1.37 (t, J=7.4 Hz, 3H), 4.34 (q, J=7.4 Hz, 2H), 4.82 
(bs, 2H), 6.98 (dd, J=8.6 and 2.0 Hz, 1H), 7.26 (s, 1H), 7.44 (d, J=8.6 Hz, 1H), 7.82 
(bs, 1H). MS (ESI): [M]+=239.7.  
5.1.3.3. Methyl 3-amino-5-methoxy-1H-indole-2-carboxylate (8f). Following general 
procedure B, the crude residue was purified by flash chromatography, using ethyl 
acetate:petroleum ether 1:1 (v:v) as eluent, to furnish 8f as a brown solid. Yield: 63%, 
mp 161 °C. 1H-NMR (DMSO-d6) : 3.83 (s, 3H), 3.96 (s 3H), 4.44 (bs, 2H), 6.93 (d, 
J=2.4 Hz, 1H), 7.05 (dd, J=9.0 and 2.4 Hz, 1H), 7.57 (d, J=9.0 Hz, 1H), 7.31 (d, J=9.0 
Hz, 1H), 11.8 (bs, 1H). MS (ESI): [M]+=221.3. 
5.1.4. General method C for the synthesis of compounds 10a-g. 
To a solution of the appropriate 2-alkoxycarbonyl-1H-indole derivative 9a-g (2 mmol) in 
DMF (20 mL) cooled to 0 °C was added dropwise a mixture of NBS (0.43 g, 2.4 mmol) 
in DMF (10 mL), and the resulting mixture was stirred for 1 h. The mixture was then 
diluted with cold water (30 mL) and extracted with dichloromethane (2 x 20 mL). The 
combined organics were washed with water (3x20 mL), brine (20 mL), dried (Na2SO4) 
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and evaporated to give a solid, which was purified by crystallization with the appropriate 
solvent or purified by flash chromatography on silica gel.  
5.1.4.1. Methyl 3-bromo-5-methyl-1H-indole-2-carboxylate (10a). Following general 
procedure C, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 1:9 (v:v) as eluent furnished 10a as a white solid. Yield: 77%, 
mp 162-164 °C. 1H-NMR (DMSO-d6) : 2.40 (s, 3H), 3.89 (s, 3H), 7.16 (dd, J=8.6 and 
1.2 Hz, 1H), 7.31 (d, J=8.6 Hz, 1H), 7.39 (d, J=1.2 Hz, 1H), 12.2 (s, 1H). MS (ESI): 
[M]+=268.1, 270.2. 
5.1.4.2. Methyl 3-bromo-5-methoxy-1H-indole-2-carboxylate (10b). Following general 
procedure C, petroleum ether was added to the residue, the mixture stirred for 15 min, 
and the resulting precipitate was collected by filtration to furnish the title compound 10b 
as a brown solid (>95% yield); mp 173-174 °C. 1H-NMR (DMSO-d6) : 3.85 (s, 3H), 
3.89 (s, 3H), 6.89 (d, J=2.2 Hz, 1H), 6.97 (dd, J=8.8 and 2.2 Hz, 1H), 7.36 (d, J=8.8 
Hz, 1H), 12.2 (bs, 1H). MS (ESI): [M]+=284.1, 286.2. 
5.1.4.3. Ethyl 3-bromo-5-methoxy-1H-indole-2-carboxylate (10c). Following general 
procedure C, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent furnished 10c as a white solid. Yield: 89%, 
mp 134-136 °C. 1H-NMR (DMSO-d6) : 1.36 (t, J=7.0 Hz, 3H), 3.81 (s, 3H), 4.31 (q, 
J=7.0 Hz, 2H), 6.89 (d, J=2.4 Hz, 1H), 6.97 (d, J=9.0 and 2.4 Hz, 1H), 7.37 (d, J=9.0 
Hz, 1H), 12.1 (s, 1H). MS (ESI): [M]+= 298.1, 300.1. 
5.1.4.4. n-Propyl 3-bromo-5-methoxy-1H-indole-2-carboxylate (10d). Following general 
procedure C, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 1:9 (v:v) as eluent furnished 10d as a white solid. Yield: 75%, 
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mp 146-148 °C. 1H-NMR (DMSO-d6) : 1.03 (t, J=7.4 Hz, 3H), 1.74 (m, 2H), 3.81 (s, 
3H), 4.28 (t, J=7.4 Hz, 2H), 6.89 (dd, J=2.2 Hz, 1H), 6.97 (d, J=9.0 and 2.2 Hz, 1H), 
7.37 (d, J=9.0 Hz, 1H), 12.1 (s, 1H). MS (ESI): [M]+= 312.2, 314.3.  
5.1.4.5. Isopropyl 3-bromo-5-methoxy-1H-indole-2-carboxylate (10e). Following 
general procedure C, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 1:9 (v:v) as eluent furnished 10e as a white solid. Yield: 75%, 
mp 178-179 °C. 1H-NMR (DMSO-d6) : 1.33 (d, J=6.4 Hz, 6H), 3.79 (s, 3H), 5.16 (m, 
1H), 6.87 (d, J=2.4 Hz, 1H), 6.96 (dd, J=8.8 and 2.4 Hz, 1H), 7.36 (d, J=9.2 Hz, 1H), 
12.0 (s, 1H). MS (ESI): [M]+= 312.2, 314.2.  
5.1.4.6. Methyl 3-bromo-6-methoxy-1H-indole-2-carboxylate (10f). Following general 
procedure C, petroleum ether was added to the residue, the mixture stirred for 15 min, 
and the resulting precipitate was collected by filtration to furnish the title compound 10f 
as a brown solid (>95% yield); mp 160-162 °C. 1H-NMR (CDCl3) : 3.86 (s, 3H), 3.97 
(s, 3H), 6.78 (d, J=2.2 Hz, 1H), 6.86 (dd, J=8.8  and 2.2 Hz, 1H), 7.34 (d, J=8.8 Hz, 
1H), 8.92 (bs, 1H). MS (ESI): [M]+= 284.1, 286.1. 
5.1.4.7. Methyl 3-bromo-7-methoxy-1H-indole-2-carboxylate (10g). Following general 
procedure C, the crude residue purified by flash chromatography using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent furnished 10g as a white solid. Yield: 81%, 
mp 176-178 °C. 1H-NMR (CDCl3) : 3.97 (s, 3H), 3.98 (s, 3H), 6.75 (d, J=5.0 Hz, 1H), 
7.13 (t, J=8.8 Hz, 1H), 7.23 (d, J=5.0 Hz, 1H), 9.12 (bs, 1H). MS (ESI): [M]+= 284.1, 
286.1. 
5.1.5. General method D for the synthesis of compounds 11a-p. 
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To a mixture of the appropriate 2-alkoxycarbonyl-3-bromo-1H-indole derivative 10a-g 
(2 mmol) in DMF (10 mL) cooled at +4 °C (ice-water bath) was added sodium hydride 
(60% in mineral oil, 96 mg, 2.2 mmol, 1.1 equiv.) in small portions. After stirring for 30 
min at room temperature, the appropriate alkyl halide (methyl, ethyl or propyl iodide) or 
benzyl bromide (4 mmol, 2 equiv.) was slowly added at +4 °C (ice-water bath), and the 
mixture was stirred for 4 h at room temperature. After this time, the reaction mixture 
was quenched by addition of a saturated aqueous solution of NH4Cl (10 mL) and the 
product extracted with dichloromethane (3 x 10 mL). The combined organic extracts 
were washed with water (10 mL), brine, dried over Na2SO4 and concentrated under 
reduced pressure to furnish a residue that was purified by crystallization with the 
appropriate solvent or purified by flash chromatography on silica gel. 
5.1.5.1. Methyl 3-bromo-5-methyl-1-methyl-1H-indole-2-carboxylate (11a). Following 
general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating agent, the 
crude residue was purified by flash chromatography, using EtOAc:petroleum ether 1:9 as 
eluent, to furnish 11a as a white solid. Yield: 77%, mp 120-121 °C. 1H-NMR (DMSO-
d6) : 2.42 (s, 3H), 3.90 (s, 3H), 3.97 (s, 3H), 7.20 (dd, J=8.6 and 1.2 Hz, 1H), 7.34 (d, 
J=1.2 Hz, 1H), 7.53 (d, J=8.6 Hz, 1H). MS (ESI): [M+1]+=282.1, 284.1. 
5.1.5.2. Methyl 3-bromo-5-methyl-1-benzyl-1H-indole-2-carboxylate (11b). Following 
general procedure D, using benzyl bromide (342 mg, 0.25 mL) as alkylating agent, the 
crude residue was purified by flash chromatography, using EtOAc:petroleum ether 
0.5:9.5 as eluent, to furnish 11b as a colorless oil. Yield: 81%. 1H-NMR (DMSO-d6) : 
2.42 (s, 3H), 3.84 (s, 3H), 5.80 (s, 2H), 6.97 (m, 2H), 7.23 (m, 4H), 7.38 (s, 1H), 7.55 
(d, J=8.8 Hz, 1H). MS (ESI): [M+1]+=358.0, 360.2.  
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5.1.5.3. Methyl 3-bromo-5-methoxy-1-methyl-1H-indole-2-carboxylate (11c). Following 
general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating agent, the 
crude residue was purified by flash chromatography, using EtOAc:petroleum ether 1:9 as 
eluent, to furnish 11c as a white solid. Yield: 64%, mp 110-111 °C. 1H-NMR (DMSO-
d6) : 3.82 (s, 3H), 3.90 (s, 3H), 3.97 (s, 3H), 6.93 (d, J=2.2 Hz, 1H), 7.02 (dd, J=9.4 
and 2.2 Hz, 1H), 7.57 (d, J=9.4 Hz, 1H). MS (ESI): [M+1]+=298.3, 300.3. 
5.1.5.4. Methyl 3-bromo-5-methoxy-1-ethyl-1H-indole-2-carboxylate (11d). Following 
general procedure D, using iodoethane (312 mg, 0.16 mL) as alkylating agent, the crude 
residue was purified by flash chromatography, using EtOAc:petroleum ether 1:9 as 
eluent, to furnish 11d as an orange oil. Yield: >95%. 1H-NMR (CDCl3) : 1.37 (t, J=7.2 
Hz, 3H), 3.89 (s, 3H), 3.97 (s, 3H), 4.56 (q, J=7.2 Hz, 2H), 7.03 (d, J=2.2 Hz, 1H), 7.15 
(d, J=8.8 and 2.2 Hz, 1H), 7.36 (d, J=8.8 Hz, 1H). MS (ESI): [M+1]+=312.1, 314.2. 
5.1.5.5. Methyl 3-bromo-5-methoxy-1-n-propyl-1H-indole-2-carboxylate (11e). 
Following general procedure D, using 1-iodopropane (0.34 g, 0.20 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 1:9 as eluent, to furnish 11e as a colorless oil. Yield: 83%. 1H-NMR (DMSO-d6) : 
0.80 (t, J=7.4 Hz, 3H), 1.65 (m, 2H), 3.82 (s, 3H), 3.90 (s, 3H), 4.47 (t, J=7.2 Hz, 2H), 
6.92 (d, J=2.4 Hz, 1H), 7.03 (dd, J=9.2 and 2.4 Hz, 1H), 7.61 (d, J=9.2 Hz, 1H). MS 
(ESI): [M+1]+=326.3, 328.3. 
5.1.5.6. Methyl 3-bromo-5-methoxy-1-benzyl-1H-indole-2-carboxylate (11f). Following 
general procedure D, using benzyl bromide (342 mg, 0.25 mL) as alkylating agent, the 
crude residue was purified by flash chromatography, using EtOAc:petroleum ether 1:9 as 
eluent, to furnish 11f as a white solid. Yield: 73%, mp 112-114 °C. 1H-NMR (DMSO-
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d6) : 3.80 (s, 3H), 3.83 (s, 3H), 5.78 (s, 2H), 6.95 (m, 3H), 7.02 (d, J=9.2 and 2.4 Hz, 
1H), 7.19 (m, 3H), 7.58 (d, J=9.2 Hz, 1H). MS (ESI): [M+1]+=374.1, 376.3.  
5.1.5.7. Ethyl 3-bromo-5-methoxy-1-methyl-1H-indole-2-carboxylate (11g). Following 
general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating agent, the 
crude residue was purified by flash chromatography, using EtOAc:petroleum ether 1:9 as 
eluent, to furnish 11g as a cream colored solid. Yield: 67%, mp 123-124 °C.  1H-NMR 
(DMSO-d6) : 1.34 (t, J=7.2 Hz, 3H), 3.82 (s, 3H), 3.97 (s, 3H), 4.32 (q, J=7.0 Hz, 
2H), 6.92 (d, J=2.4 Hz, 1H), 7.04 (d, J=9.0 and 2.4 Hz, 1H), 7.56 (d, J=9.0 Hz, 1H). 
MS (ESI): [M+1]+=312.2, 314.2. 
5.1.5.8. Ethyl 3-bromo-5-methoxy-1-benzyl-1H-indole-2-carboxylate (11h). Following 
general procedure D, using benzyl bromide (342 mg, 0.25 mL) as alkylating agent, the 
crude residue was purified by flash chromatography, using EtOAc:petroleum ether 2:8 as 
eluent, to furnish 11h as a white solid. Yield: 71%, mp 124-126 °C. 1H-NMR (DMSO-
d6) : 1.34 (t, J=7.2 Hz, 3H), 3.87 (s, 3H), 4.20 (q, J=7.2 Hz, 2H), 5.78 (s, 2H), 6.88 (d, 
J=1.2 Hz, 1H), 6.93 (m, 1H), 7.03 (dd, J=9.2 and 1.2 Hz, 1H), 7.21 (m, 4H), 7.63 (d, 
J=8.8 Hz, 1H). MS (ESI): [M+1]+=388.1, 390.2. 
5.1.5.9. n-Propyl 3-bromo-5-methoxy-1-methyl-1H-indole-2-carboxylate (11i). 
Following general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 1:9 as eluent, to furnish 11i as a white solid. Yield: 58%, mp 141-143 °C. 1H-NMR 
(DMSO-d6) : 1.03 (t, J=7.2 Hz, 3H), 1.75 (m, 2H), 3.82 (s, 3H), 3.98 (s, 3H), 4.26 (t, 
J=7.2 Hz, 2H), 6.92 (d, J=2.4 Hz, 1H), 7.04 (dd, J=9.0 and 2.4 Hz, 1H), 7.57 (d, J=9.0 
Hz, 1H). MS (ESI): [M+1]+=326.2, 328.3. 
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5.1.5.10. n-Propyl 3-bromo-5-methoxy-1-benzyl-1H-indole-2-carboxylate (11j). 
Following general procedure D, using benzyl bromide (342 mg, 0.25 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 0.5:9.5 as eluent, to furnish 11j as a colorless oil. Yield: 72%. 1H-NMR (DMSO-
d6) : 0.94 (t, J=7.2 Hz, 3H), 1.67 (m, 2H), 3.83 (s, 3H), 4.23 (t, J=6.4 Hz, 2H), 5.80 (s, 
2H), 6.95 (m, 4H), 7.06 (dd, J=9.0 and 2.2 Hz, 1H), 7.23 (m, 2H), 7.56 (d, J=9.0 Hz, 
1H). MS (ESI): [M+1]+=403.1, 405.1. 
5.1.5.11. Isopropyl 3-bromo-5-methoxy-1-methyl-1H-indole-2-carboxylate (11k). 
Following general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 1:9 as eluent, to furnish 11k as a white solid. Yield: 75%, mp 102-104 °C. 1H-
NMR (DMSO-d6) : 1.36 (d, J=6.4 Hz, 6H), 3.82 (s, 3H), 3.96 (s, 3H), 5.20 (m, 1H), 
6.91 (d, J=2.2 Hz, 1H), 7.03 (dd, J=9.2 and 2.4 Hz, 1H), 7.56 (d, J=9.2 Hz, 1H). MS 
(ESI): [M+1]+=326.1, 328.2. 
5.1.5.12. Isopropyl 3-bromo-5-methoxy-1-benzyl-1H-indole-2-carboxylate (11l). 
Following general procedure D, using benzyl bromide (342 mg, 0.25 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 0.5:9.5 as eluent, to furnish 11l as a colorless, viscous oil. Yield: 81%. 1H-NMR 
(DMSO-d6) : 1.25 (d, J=6.2 Hz, 6H), 3.82 (s, 3H), 5.13 (m, 1H), 5.76 (s, 2H), 6.96 (m, 
3H), 6.99 (dd, J=9.0 and 2.4 Hz, 1H), 7.07 (m, 3H), 7.58 (d, J=9.0 Hz, 1H). MS (ESI): 
[M+1]+=402.1, 404.1. 
5.1.5.13. Methyl 3-bromo-6-methoxy-1-methyl-1H-indole-2-carboxylate (11m). 
Following general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating 
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agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 1:9 as eluent, to furnish 11m as a white solid. Yield: 82%, mp 108-110 °C. 1H-
NMR (CDCl3) : 3.89 (s, 3H), 3.96 (s, 3H), 3.99 (s, 3H), 6.72 (d, J=2.2 Hz, 1H), 6.86 
(dd, J=8.8 and 2.2 Hz, 1H), 7.51 (d, J=8.8 Hz, 1H). MS (ESI): [M+1]+=298.3, 300.3. 
5.1.5.14. Methyl 3-bromo-6-methoxy-1-ethyl-1H-indole-2-carboxylate (11n). Following 
general procedure D, using iodoethane (312 mg, 0.16 mL) as alkylating agent, the crude 
residue was purified by flash chromatography, using EtOAc:petroleum ether 1:9 as 
eluent, to furnish 11n as a white solid. Yield: 74%, mp 105-106 °C. 1H-NMR (CDCl3) : 
1.34 (t, J=7.0 Hz, 3H), 3.89 (s, 3H), 3.96 (s, 3H), 4.51 (q, J=7.0 Hz, 2H), 6.73 (d, J=2.0 
Hz, 1H), 6.86 (dd, J=9.0 and 2.0 Hz, 2H), 7.52 (d, J=9.0 Hz, 1H). MS (ESI): 
[M+1]+=312.1, 314.2. 
5.1.5.15. Methyl 3-bromo-6-methoxy-1-benzyl-1H-indole-2-carboxylate (11o). 
Following general procedure D, using benzyl bromide (342 mg, 0.25 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 1:9 as eluent, to furnish 11o as a yellow oil. Yield: 68%. 1H-NMR (CDCl3) : 3.80 
(s, 3H), 3.88 (s, 3H), 5.75 (s, 2H), 6.69 (d, J=2.2 Hz, 1H), 6.87 (d, J=8.8 and 2.2 Hz, 
1H), 7.02 (m, 2H), 7.24 (m, 3H), 7.55 (d, J=8.8 Hz, 1H). MS (ESI): [M+1]+=374.1, 
376.1. 
5.1.5.16. Methyl 3-bromo-7-methoxy-1-methyl-1H-indole-2-carboxylate (11p). 
Following general procedure D, using iodomethane (284 mg, 0.12 mL) as alkylating 
agent, the crude residue was purified by flash chromatography, using EtOAc:petroleum 
ether 1:9 as eluent, to furnish 11p as a white solid. Yield: 86%, mp 122-124 °C.  1H-
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NMR (CDCl3) : 3.93 (s, 3H), 3.96 (s, 3H), 4.30 (s, 3H), 6.72 (d, J=9.6 Hz, 1H), 7.06 
(t, J=9.6 Hz, 1H), 7.22 (d, J=9.6 Hz, 1H). MS (ESI): [M+1]+=298.2, 300.2. 
5.1.6. General method E for the synthesis of compounds 3a-ac. 
To a dry Schlenk tube, 3-amino-2-alkoxycarbonyl-1H-indole derivative 8a-h or N-1-
substituted 2-alkoxycarbonyl-3-bromoindole 11a-p (0.5 mmol) was dissolved in dry 
toluene (5 mL). Pd(OAc)2 (6 mol%, 30 mg), rac-BINAP (4 mol%, 30 mg), Cs2CO3 (228 
mg, 0.7 mmol, 1.4 equiv.) and 5-bromo-1,2,3-trimethoxybenzene (148 mg, 0.6 mmol, 
1.2 equiv.) for the synthesis of compounds 3a-h, 5-bromo-1,3-dimethoxybenzene (130 
mg, 0.6 mmol, 1.2 equiv.) for the preparation of derivatives 3i-j, 3,4,5-trimethoxyaniline 
(183 mg, 1 mmol, 2 equiv.) for the synthesis of compounds 3k-z or 3,5-dimethoxyaniline 
(153 mg, 1 mmol, 2 equiv.) for the preparation of derivatives 3a-j were added under 
argon, and the mixture was heated with stirring at 120 °C for 18 h. Upon cooling, 
dichloromethane was added (5 mL), the mixture was filtered through Celite under 
vacuum and the filtrate diluted with dichloromethane (10 mL) and water (5 mL). The 
aqueous phase was separated and additionally extracted with dichloromethane (2x5 mL). 
The combined organic phases were washed with brine (5 mL), dried over Na2SO4 and 
concentrated under reduced pressure to give a residue purified by flash column 
chromatography on silica gel.  
5.1.6.1. Methyl 3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate (3a). 
Following general procedure E, the crude residue obtained from 8a and 5-bromo-1,2,3-
trimethoxybenzene was purified by flash chromatography, using ethyl acetate:petroleum 
ether 3:7 (v:v) as eluent, to furnish 3a as a green solid. Yield: 61%, mp 193 °C. 1H-NMR 
(DMSO-d6) : 3.57 (s, 3H), 3.58 (s, 6H), 3.83 (s, 3H), 6.23 (s, 2H), 6.92 (t, J=6.8 Hz, 
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1H), 7.22 (t, J=6.8 Hz, 1H), 7.26 (d, J=9.0 Hz, 1H), 7.33 (d, J=9.0 Hz, 1H), 7.69 (s, 
1H), 11.4 (s, 1H). 13C-NMR (DMSO-d6) : 51.82, 55.89 (2C), 60.63, 94.34 (2C), 
113.37, 114.75, 118.93, 120.78, 122.22, 125.93, 127.46, 131.20, 136.43, 141.25, 
153.52 (2C), 162.57. MS (ESI): [M+1]+=357.2. Anal. calcd for C19H20N2O5: C, 64.04; 
H, 5.66; N, 7.86; found: C, 63.89; H, 5.51; N, 7.64. 
5.1.6.2. Ethyl 3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate (3b). 
Following general procedure E, the crude residue obtained from 8b and 5-bromo-1,2,3-
trimethoxybenzene was purified by flash chromatography, using ethyl acetate:petroleum 
ether 3:7 (v:v) as eluent, to furnish 3b as a green solid. Yield: 45%, mp 121-122 °C. 1H-
NMR (CDCl3) : 1.30 (t, J=7.2 Hz, 3H), 3.58 (s, 6H), 3.60 (s, 3H), 4.30 (q, J=7.2 Hz, 
2H), 6.24 (s, 2H), 6.72 (t, J=8.4 Hz, 1H), 7.26 (m, 1H), 7.39 (m, 2H), 7.69 (s, 1H), 11.4 
(s, 1H). 13C-NMR (DMSO-d6) : 14.25, 55.37 (2C), 59.91, 60.09, 93.63 (2C), 112.84, 
114.57, 118.46, 120.49, 121.54, 125.37, 126.84, 130.59, 135.80, 140.94, 153.02 (2C), 
161.63. MS (ESI): [M+1]+=371.21. Anal. calcd for C20H22N2O5: C, 64.85; H, 5.99; N, 
7.56; found: C, 64.67; H, 5.78; N, 7.34. 
5.1.6.3. tert-butyl 3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate (3c). 
Following general procedure E, the crude residue obtained from 8c and 5-bromo-1,2,3-
trimethoxybenzene was purified by flash chromatography, using ethyl acetate:petroleum 
ether 2:8 (v:v) as eluent, to furnish 3c as a yellow solid. Yield: 44%, mp 235 °C. 1H-
NMR (CDCl3) : 1.65 (s, 9H), 3.73 (s, 6H), 3.82 (s, 3H), 6.30 (s, 2H), 6.97 (m, 1H), 
7.32 (m, 2H), 7.43 (d, J=9.0 Hz, 1H), 7.48 (d, J=9.0 Hz, 1H), 8.12 (bs, 1H). 13C-NMR 
(CDCl3) : 28.63 (3C), 56.01 (2C), 61.18, 81.96, 95.83 (2C), 112.08, 113.79, 118.97, 
120.36, 123.09, 126.23, 129.74, 132.57, 135.59, 140.00, 153.64 (2C), 162.14. MS 
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(ESI): [M+1]+=399.4. Anal. calcd for C22H26N22O5: C, 66.32; H, 6.58; N, 7.03; found: 
C, 66.12; H, 6.35; N, 6,89.  
5.1.6.4. Benzyl 3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate (3d). 
Following general procedure E, the crude residue obtained from 8d and 5-bromo-1,2,3-
trimethoxybenzene was purified by flash chromatography, using ethyl acetate:petroleum 
ether 2:8 (v:v) as eluent, to furnish 3d as a yellow solid. Yield: 52%, mp 171 °C. 1H-
NMR (CDCl3) : 3.72 (s, 6H), 3.82 (s, 3H), 5.38 (s, 2H), 6.23 (s, 2H), 7.02 (m, 1H), 
7.29 (d, J=3.4 Hz, 1H), 7.41 (m, 8H), 8.12 (s, 1H). 13C-NMR (CDCl3) : 56.01 (2C), 
61.18, 66.41, 96.25 (2C), 112.08, 112.20, 119.09, 120.05, 123.21, 126.72, 128.53 (2C), 
128.62, 128.82 (2C), 131.10, 132.85, 135.89, 136.22, 139.58, 153.64 (2C), 162.28. MS 
(ESI): [M+1]+=433.47. Anal. calcd for C25H24N2O5: C, 69.43; H, 5.59; N, 6.48; found: 
C, 69.16; H, 5.37; N, 6.24.  
5.1.6.5. Ethyl 6-chloro-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate 
(3e). Following general procedure E, the crude residue obtained from 8e and 5-bromo-
1,2,3-trimethoxybenzene was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3e as a yellow solid. Yield: 52%, 
mp 195 °C. 1H-NMR (CDCl3) : 1.42 (t, J=7.2 Hz, 3H), 3.74 (s, 6H), 3.82 (s, 3H), 4.39 
(q, J=7.0 Hz, 2H), 6.29 (s, 2H), 6.92 (dd, J=7.8 and 1.6 Hz, 1H), 7.32 (dd, J=7.8 and 
1.6 Hz, 1H),), 7.40 (m, 2H), 8.20 (bs, 1H). 13C-NMR (CDCl3) : 30.92, 55.98 (2C), 
60.68, 61.08, 96.61 (2C), 111.79, 112.62, 118.02, 119.89, 124.04, 132.46, 136.81, 
138.13, 139.14, 152.12, 153.60 (2C), 162.20. MS (ESI): [M+1]+=405.4. Anal. calcd for 
C20H21ClN2O5: C, 59.33; H, 5.23; N, 6.92; found: C, 59.05; H, 5.02; N, 6.77.  
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5.1.6.6. Methyl 5-methoxy-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate 
(3f). Following general procedure E, the crude residue obtained from 8f and 5-bromo-
1,2,3-trimethoxybenzene was purified by flash chromatography, using ethyl 
acetate:petroleum ether 4:6 (v:v) as eluent, to furnish 3f as a yellow solid. Yield: 53%, 
mp 107 °C. 1H-NMR (CDCl3) : 3.57 (s, 3H), 3.61 (s, 6H), 3.63 (s, 3H), 3.83 (s, 3H), 
6.19 (s, 2H), 6.69 (d, J=2.4 Hz, 1H), 6.93 (dd, J=9.2 and 2.4 Hz, 1H), 7.29 (d, J=9.2 
Hz, 1H), 7.63 (s, 1H), 11.3 (s, 1H). 13C-NMR (CDCl3) : 51.25, 55.09, 55.40 (2C), 
60.10, 93.29 (2C), 101.24, 113.94, 115.45, 117.16, 120.70, 126.06, 130.35, 131.27, 
141.09, 152.41, 153.03 (2C), 161.86. MS (ESI): [M+1]+=387.4. Anal. calcd for 
C20H22N2O6: C, 62.17; H, 5.74; N, 7.25; found: C, 62.01; H, 5.37; N, 7.01. 
5.1.6.7. Ethyl 5-methoxy-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate 
(3g). Following general procedure E, the crude residue obtained from 8g and 5-bromo-
1,2,3-trimethoxybenzene was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3g as a yellow solid. Yield: 43%, 
mp 165-166 °C. 1H-NMR (DMSO-d6) : 1.27 (t, J=7.2 Hz, 3H), 3.57 (s, 3H), 3.61 (s, 
6H), 3.64 (s, 3H), 4.27 (q, J=7.2 Hz, 2H), 6.17 (s, 2H), 6.74 (d, J=2.8 Hz, 1H), 6.93 
(dd, J=9.2 and 2.8 Hz, 1H), 7.31 (d, J=8.8 Hz, 1H), 7.60 (s, 1H), 11.3 (s, 1H). 13C-
NMR (CDCl3) : 14.19, 55.09, 55.39 (2C), 59.83, 60.07, 93.06 (2C), 101.03, 113.91 
(2C), 115.87, 117.10, 121.02, 125.91, 131.14, 141.38, 152.51, 153.03 (2C), 161.43. 
MS (ESI): [M+1]+=401.34. Anal. calcd for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; 
found: C, 62.73; H, 5.89; N, 6.87.  
5.1.6.8. Methyl 6-methoxy-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-carboxylate 
(3h). Following general procedure E, the crude residue obtained from 8h and 5-bromo-
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1,2,3-trimethoxybenzene was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3h as a yellow solid. Yield: 52%, 
mp 144-146 °C. 1H-NMR (CDCl3) : 3.74 (s, 3H), 3.85 (s, 6H), 3.89 (s, 3H), 4.00 (s, 
3H), 6.44 (s, 2H), 6.62 (d, J=9.2 Hz, 1H), 6.91 (dd, J=9.2 and 2.4 Hz, 1H), 7.02 (d, 
J=2.4 Hz, 1H), 8.10 (s, 1H), 11.3 (bs, 1H). 13C-NMR (CDCl3) : 51.21, 55.13, 55.40 
(2C), 60.02, 93.33 (2C), 101.55, 113.78, 115.40, 117.54, 121.12, 126.33, 130.29, 
131.31, 141.00, 152.40, 153.12 (2C), 161.55. MS (ESI): [M+1]+=387.3. Anal. calcd for 
C20H22N2O6: C, 62.17; H, 5.74; N, 7.25; found: C, 61.92; H, 5.52; N, 7.03.  
5.1.6.9. Methyl 3-[(3,5-dimethoxyphenyl)amino]-1H-indole-2-carboxylate (3i). 
Following general procedure E, the crude residue obtained from 8a and 5-bromo-1,3-
dimethoxybenzene was purified by flash chromatography, using ethyl acetate:petroleum 
ether 2:8 (v:v) as eluent, to furnish 3i as an orange solid. Yield: 80%, mp 138-140 °C. 
1H-NMR (CDCl3) : 3.71 (s, 6H), 3.94 (s, 3H), 6.10 (bs, 1H), 6.22 (s, 2H), 6.99 (m, 
1H), 7.32 (m, 3H), 7.52 (d, J=8.4 Hz, 1H), 8.25 (bs, 1H). 13C-NMR (DMSO-d6) : 
51.30, 54.71 (2C), 91.02, 93.89, 111.98, 112.79, 115.60, 117.59, 118.70, 120.39, 
121.18, 125.24, 125.76, 135.65, 146.99, 160.76, 161.78. MS (ESI): [M+1]+=327.3. 
Anal. calcd for C18H18N2O4: C, 66.25; H, 5.56; N, 8.58; found: C, 66.02; H, 5.35; N, 
8.35.  
5.1.6.10. Ethyl 3-[(3,5-dimethoxyphenyl)amino]-1H-indole-2-carboxylate (3j). 
Following general procedure E, the crude residue obtained from 8b and 5-bromo-1,3-
dimethoxybenzene was purified by flash chromatography, using ethyl acetate:petroleum 
ether 2:8 (v:v) as eluent, to furnish 3j as a yellow solid. Yield: 52%, mp 142 °C. 1H-
NMR (CDCl3) : 1.41 (t, J=7.0 Hz, 3H), 3.71 (s, 6H), 4.42 (q, J=7.0 Hz, 2H), 6.10 (s, 
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1H), 6.22 (s, 2H), 6.99 (t, J=8.4 Hz, 1H), 7.33 (m, 3H), 7.53 (t, J=8.4 Hz, 1H), 8.22 (bs, 
1H). 13C-NMR (CDCl3) : 14.15, 54.70 (2C), 59.92, 90.93, 93.71 (2C), 112.78, 115.94, 
118.75, 120.25, 121.20, 121.40, 125.21, 125.67, 135.55, 147.18 (2C), 160.78. MS 
(ESI): [M+1]+=341.4. Anal. calcd for C19H20N2O4: C, 67.05; H, 5.92; N, 8.23; found: C, 
66.89; H, 5.73; N, 8.03.   
5.1.6.11. Methyl 1,5-dimethyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3k). Following general procedure E, the crude residue obtained from 11a 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3k as a yellow solid. Yield: 42%, 
mp 134-136 °C. 1H-NMR (DMSO-d6) : 2.31 (s, 3H), 3.58 (s, 3H), 3.59 (s, 6H), 3.83 
(s, 3H), 3.90 (s, 3H), 6.21 (s, 2H), 7.16 (d, J=1.2 Hz, 1H), 7.22 (dd, J=9.2 and 1.2 Hz, 
1H), 7.45 (d, J=9.2 Hz, 1H), 7.74 (s, 1H). 13C-NMR (DMSO-d6) : 20.86, 31.91, 51.36, 
55.39 (2C), 60.10, 93.68 (2C), 110.77, 116.41, 119.80, 120.82, 127.15, 127.50, 127.66, 
130.66, 136.44, 140.98, 153.01 (2C), 162.29. MS (ESI): [M+1]+=384.9. Anal. calcd for 
C21H24N2O5: C, 65.61; H, 6.29; N, 7.29; found: C, 65.36; H, 6.07; N, 7.13. 
5.1.6.12. Methyl 5-methyl-1-benzyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3l). Following general procedure E, the crude residue obtained from 11b 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3l as a yellow solid. Yield: 49%, 
mp 138-139 °C. 1H-NMR (DMSO-d6) : 2.30 (s 3H), 3.59 (s, 3H), 3.60 (s, 6H), 3.75 (s, 
3H), 5.73 (s, 2H), 6.22 (s, 2H), 6.96 (dd, J=8.8 and 1.2 Hz, 1H), 7.18 (m, 3H), 7.23 (m, 
3H), 7.49 (d, J=8.8 Hz, 1H), 7.81 (s, 1H). 13C-NMR (DMSO-d6) : 20.85, 47.26, 51.32, 
55.41 (2C), 60.12, 88.66, 93.90 (2C), 111.22, 115.82, 120.28, 120.96, 126.05 (2C), 
 47 
126.89, 128.01, 128.20, 128.35 (2C), 120.75, 136.55, 138.77, 140.89, 153.01 (2C), 
162.10. MS (ESI): [M+1]+=461.4. Anal. calcd for C27H28N2O5: C, 70.42; H, 6.13; N, 
6.08; found: C, 70.21; H, 6.01; N, 5.88. 
5.1.6.13. Methyl 5-methoxy-1-methyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3m). Following general procedure E, the crude residue obtained from 11c 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3m as a yellow solid. Yield: 51%, 
mp 114-115 °C. 1H-NMR (DMSO-d6) : 3.57 (s, 3H), 3.61 (s, 6H), 3.63 (s, 3H), 3.82 
(s, 3H), 3.91 (s, 3H), 6.18 (s, 2H), 6.70 (d, J=2.4 Hz, 1H), 7.00 (d, J=9.2 and 2.4 Hz, 
1H), 7.49 (d, J=9.2 Hz, 1H), 7.69 (s, 1H). 13C-NMR (CDCl3) : 31.97, 51.34, 55.14, 
55.40 (2C), 60.07, 93.49 (2C), 101.43, 109.34, 112.18, 117.18, 118.73, 119.88, 126.88, 
133.33, 141.10, 152.60, 153.01 (2C), 161.16. MS (ESI): [M+1]+=401.4. Anal. calcd for 
C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; found: C, 62.77; H, 5.89; N, 6.78. 
5.1.6.14. Methyl 5-methoxy-1-ethyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3n). Following general procedure E, the crude residue obtained from 11d 
and 3,4,5-trimethoxyaniline was purified by flash chromatography using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3n as a yellow solid. Yield: 48%, 
mp 150-151 °C. 1H-NMR (DMSO-d6) : 1.21 (t, J=7.2 Hz, 3H), 3.57 (s, 3H), 3.61 (s, 
6H), 3.63 (s, 3H), 3.81 (s, 3H), 4.47 (q, J=7.2 Hz, 2H), 6.17 (s, 2H), 6.71 (d, J=2.4 Hz, 
1H), 7.00 (d, J=2.4 and 9.2 Hz, 1H), 7.51 (d, J=9.2 Hz, 1H), 7.70 (s, 1H). 13C-NMR 
(DMSO-d6) : 13.99, 15.49, 51.36, 55.16, 55.42 (2C), 60.09, 93.56 (2C), 101.62, 
112.05, 116.01, 117.24, 120.12, 127.22, 130.49, 132.41, 141.10, 152.65, 153.02 (2C), 
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161.98. MS (ESI): [M+1]+=414.8. Anal. calcd for C22H26N2O6: C, 63.76; H, 6.32; N, 
6.76; found: C, 63.57; H, 6.11; N, 6.47. 
5.1.6.15. Methyl 5-methoxy-1-n-propyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-
2-carboxylate (3o). Following general procedure E, the crude residue obtained from 11e 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3o as a yellow solid. Yield: 48%, 
mp 130-132 °C. 1H-NMR (DMSO-d6) : 0.79 (t, J=7.6 Hz, 3H), 1.63 (m, 2H), 3.57 (s, 
3H), 3.60 (s, 6H), 3.63 (s, 3H), 3.80 (s, 3H), 4.41 (t, J=7.2 Hz, 2H), 6.16 (s, 2H), 6.71 
(d, J=2.8 Hz, 1H), 7.01 (dd, J=9.2 and 2.8 Hz, 1H), 7.52 (d, J=9.2 Hz, 1H), 7.69 (s, 
1H). 13C-NMR (DMSO-d6) : 11.49, 24.02, 46.17, 51.88, 55.68, 55.93 (2C), 60.62, 
93.95 (2C), 101.95, 112.89, 117.06, 117.71, 120.59, 127.60, 130.95, 133.48, 141.78, 
153.17, 153.55 (2C), 162.59. MS (ESI): [M+1]+=429.5. Anal. calcd for C23H28N2O6: C, 
64.47; H, 6.59; N, 6.54; found: C, 64.21; H, 6.33; N, 6.36. 
5.1.6.16. Methyl 5-methoxy-1-benzyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3p). Following general procedure E, the crude residue obtained from 11f 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3p as a brown solid. Yield: 48%, 
mp 138-139 °C. 1H-NMR (DMSO-d6) : 3.58 (s, 3H), 3.61 (s, 6H), 3.64 (s, 3H), 3.73 
(s, 3H), 5.74 (s, 2H), 6.19 (s, 2H), 6.83 (d, J=2.4 Hz, 1H), 6.99 (m, 3H), 7.22 (m, 3H), 
7.63 (d, J=9.2 Hz, 1H), 7.77 (s, 1H). 13C-NMR (CDCl3) : 47.32, 51.30, 55.14, 55.42 
(2C), 60.09, 93.71 (2C), 101.62, 112.61, 116.56, 117.46, 120.47, 126.04 (2C), 126.91, 
127.94, 128.36 (2C), 130.61, 133.37, 138.77, 141.06, 152.89, 153.02 (2C), 161.98. MS 
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(ESI): [M+1]+=477.5. Anal. calcd for C27H28N2O6: C, 68.05; H, 5.92; N, 5.88; found: C, 
67.88; H, 5.71; N, 5.63. 
5.1.6.17. Ethyl 5-methoxy-1-methyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3q). Following general procedure E, the crude residue obtained from 11g 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3q as a yellow solid. Yield: 46%, 
mp 94-95 °C. 1H-NMR (DMSO-d6) : 1.22 (t, J=7.2 Hz, 3H), 3.55 (s, 3H), 3.58 (s, 6H), 
3.64 (s, 3H), 3.90 (s, 3H), 4.22 (q, J=7.2 Hz, 2H), 6.13 (s, 2H), 6.75 (d, J=2.4 Hz, 1H), 
6.99 (dd, J=9.2 and 2.4 Hz, 1H), 7.47 (d, J=9.2 Hz, 1H), 7.63 (s, 1H). 13C-NMR 
(CDCl3) : 13.92, 31.99. 55.16, 55.37 (2C), 60.06, 92.98 (2C), 101.09, 112.16, 117.15, 
117.65, 120.33, 126.59, 130.26, 133.17, 141.53, 152.75, 153.05 (2C), 161.71. MS 
(ESI): [M+1]+=415.0. Anal. calcd for C22H26N2O6: C, 63.76; H, 6.32; N, 6.76; found: C, 
63.55; H, 6.122; N, 6.48. 
5.1.6.18. Ethyl 5-methoxy-1-benzyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3r). Following general procedure E, the crude residue obtained from 11h 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3r as a yellow solid. Yield: 46%, 
mp 129-130 °C. 1H-NMR (DMSO-d6) : 1.10 (t; J=6.8 Hz, 3H), 3.57 (s, 3H), 3.61 (s, 
6H), 3.67 (s, 3H), 4.15 (q, J=7.2 Hz, 2H), 5.74 (s, 2H), 6.16 (s, 2H), 6.84 (d, J=2.8 Hz, 
1H), 6.94 (d, J=6.8 Hz, 2H), 6.98 (dd, J=9.2 and 2.8 Hz, 1H), 7.23 (m, 3H), 7.54 (d, 
J=9.2 Hz, 1H), 7.74 (s, 1H). 13C-NMR (DMSO-d6) : 13.72, 47.34, 55.15, 55.36 (2C), 
60.04, 93.12 (2C), 99.16, 101.26, 112.54, 117.15, 117.43, 118.42, 120.92, 125.92 (2C), 
126.86, 127.64, 128.31 (2C), 130.16, 133.20, 138.80, 141.51, 153.03 (2C), 161.54. MS 
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(ESI): [M+1]+=491.3. Anal. calcd for C28H30N2O6: C, 68.56; H, 6.16; N, 5.71; found: C, 
68.32; H, 6.02; N, 5.52. 
5.1.6.19. n-Propyl 5-methoxy-1-methyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-
2-carboxylate (3s). Following general procedure E, the crude residue obtained from 11i 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3s as a yellow solid. Yield: 43%, 
mp 112-113 °C. 1H-NMR (DMSO-d6) : 0.89 (t, J=7.2 Hz, 3H), 1.64 (m, 2H), 3.56 (s, 
3H), 3.60 (s, 6H), 3.65 (s, 3H), 3.92 (s, 3H), 4.16 (t, J=7.2 Hz, 2H), 6.14 (s, 2H), 6.76 
(d, J=2.4 Hz, 1H), 7.01 (dd, J=8.8 and 2.4 Hz, 1H), 7.49 (d, J=8.8 Hz, 1H), 7.63 (s, 
1H). 13C-NMR (DMSO-d6) : 10.40, 21.38, 32.05, 55.17, 55.39 (2C), 60.08, 65.65, 
92.98 (2C), 101.12, 112.21, 117.19, 120.33, 126.64, 133.21, 141.49, 142.53, 149.95, 
152.78, 153.06 (2C), 161.84. MS (ESI): [M+1]+=429.5. Anal. calcd for C23H28N2O6: C, 
64.47; H, 6.59; N, 6.54; found: C, 64.27; H, 6.37; N, 6.29. 
5.1.6.20. n-Propyl 5-methoxy-1-benzyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-
2-carboxylate (3t). Following general procedure E, the crude residue obtained from 11j 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3t as a yellow solid. Yield: 56%, 
mp 107-109 °C. 1H-NMR (DMSO-d6) : 0.74 (t, J=7.6 Hz, 3H), 1.52 (m, 2H), 3.57 (s, 
3H), 3.60 (s, 6H), 3.66 (s, 3H), 4.08 (t, J=6.4 Hz, 2H), 5.75 (s, 2H), 6.15 (s, 2H), 6.83 
(d, J=2.2 Hz, 1H), 6.97 (m, 2H), 7.02 (dd, J=9.0 and 2.2 Hz, 1H), 7.23 (m, 3H), 7.53 (d, 
J=9.0 Hz, 1H), 7.73 (s, 1H). 13C-NMR (DMSO-d6) : 10.77, 21.83, 47.90, 55.71, 55.91 
(2C), 60.61, 66.18, 93.63 (2C), 101.81, 113.11, 117.85, 118.00 (2C), 121.49, 126.41 
(2C), 127.41, 128.13, 128.88 (2C), 130.91, 133.75, 139.32, 142.03, 153.58 (2C), 
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162.21. MS (ESI): [M+1]+=505.3. Anal. calcd for C29H32N2O6: C, 69.03; H, 6.39; N, 
5.55; found: C, 58.78; H, 6.21; N, 5.32. 
5.1.6.21. Isopropyl 5-methoxy-1-methyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-
2-carboxylate (3u). Following general procedure E, the crude residue obtained from 11k 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3u as a yellow solid. Yield: 52%, 
mp 157-159 °C. 1H-NMR (DMSO-d6) : 1.22 (d, J=6.0 Hz, 6H), 3.54 (s, 3H), 3.58 (s, 
6H), 3.65 (s, 3H), 3.89 (s, 3H), 5.07 (m, 1H), 6.11 (s, 2H), 6.77 (d, J=2.4 Hz, 1H), 6.99 
(dd, J=9.2 and 2.4 Hz, 1H), 7.47 (d, J=9.2 Hz, 1H), 7.58 (s, 1H). 13C-NMR (DMSO-d6) 
: 21.53 (2C), 32.08, 55.19, 55.40 (2C), 60.09, 67.75, 92.82 (2C), 100.96, 112.19, 
117.15, 118.12, 120.55, 122.14, 126.45, 130.23, 133.11, 141.78, 152.85, 153.10, 
161.28. MS (ESI): [M+1]+=429.4. Anal. calcd for C23H28N2O6: C, 64.47; H, 6.59; N, 
6.54; found: C, 64.26; H, 6.34; N, 6.21. 
5.1.6.22. Isopropyl 5-methoxy-1-benzyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-
2-carboxylate (3v). Following general procedure E, the crude residue obtained from 11l 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3v as a yellow solid. Yield: 42%, 
mp 115-116 °C. 1H-NMR (DMSO-d6) : 1.05 (d, J=6.0 Hz, 6H), 3.54 (s, 3H), 3.58 (s, 
6H), 3.66 (s, 3H), 4.96 (m, 1H), 5.72 (s, 2H), 6.12 (s, 2H), 6.85 (d, J=2.4 Hz, 1H), 6.92 
(d, J=6.8 Hz, 2H), 6.94 (dd, J=9.2 and 2.4 Hz, 1H), 7.22 (m, 3H), 7.53 (d, J=9.2 Hz, 
1H), 7.71 (s, 1H). 13C-NMR (DMSO-d6) : 21.26 (2C), 47.43, 55.18, 55.36 (2C), 
60.09, 67.66, 92.93 (2C), 101.10, 112.51, 117.41, 117.66, 121.12, 125.85 (2C), 126.86, 
127.47, 128.31 (2C), 130.29, 133.12, 138.89, 141.78. 153.07, 153.14 (2C), 161.12. MS 
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(ESI): [M+1]+=505.5. Anal. calcd for C29H32N2O6: C, 69.03; H, 6.39; N, 5.55; found: C, 
68,89; H, 6.26; N, 5.37. 
5.1.6.23. Methyl 6-methoxy-1-methyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3w). Following general procedure E, the crude residue obtained from 11m 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3w as a white solid. Yield: 43%, 
mp 139-140 °C. 1H-NMR (DMSO-d6) : 3.58 (s, 3H), 3.60 (s, 6H), 3.82 (s, 3H), 3.84 
(s, 3H), 3.89 (s, 3H), 6.26 (s, 2H), 6.62 (dd, J=8.8 and 2.4 Hz, 1H), 6.99 (d, J=2.2 Hz, 
1H), 7.18 (d, J=8.8 Hz, 1H), 7.79 (s, 1H).13C-NMR (DMSO-d6) : 51.74, 55.44, 55.87, 
55.99 (2C), 60.68, 93.12, 95.12 (2C), 110.87, 113.85, 114.82, 123.42, 129.75, 131.62, 
139.98, 140.94, 153.59 (2C), 159.45, 162.82. MS (ESI): [M+1]+=401.3. Anal. calcd for 
C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; found: C, 62.78; H, 5.88; N, 6.78. 
5.1.6.24. Methyl 6-methoxy-1-ethyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3x). Following general procedure E, the crude residue obtained from 11n 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3x as a yellow oil. Yield: 52%. 1H-
NMR (DMSO-d6) : 1.24 (t, J=6.8 Hz, 3H), 3.59 (s, 3H), 3.61 (s, 6H), 3.82 (s, 3H), 
3.84 (s, 3H), 4.46 (q, J=6.8 Hz, 2H), 6.26 (s, 2H), 6.63 (dd, J=8.8 and 1.6 Hz, 1H), 6.99 
(d, J=1.6 Hz, 1H), 7.19 (d, J=8.8 Hz, 1H), 7.80 (s, 1H). 13C-NMR (DMSO-d6) : 15.18, 
51.14, 55.41 (2C), 59.66, 60.08, 80.38, 92.35, 94.61 (2C), 110.24, 113.03, 113.41, 
122.97, 129.44, 131.03, 138.46, 140.27, 152.98 (2C), 158.87, 161.99. MS (ESI): 
[M+1]+=415.3. Anal. calcd for C22H26N2O6: C, 63.76; H, 6.32; N, 6.76; found: C, 63.58; 
H, 6.11; N, 6.52.   
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5.1.6.25. Methyl 5-methoxy-1-benzyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3y). Following general procedure E, the crude residue obtained from 11o 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3y as a yellow oil. Yield: 56%. 1H-
NMR (DMSO-d6) : 3.59 (s, 3H), 3.61 (s, 6H), 3.73 (s, 3H), 3.77 (s, 3H), 5.27 (s, 2H), 
6.28 (s, 2H), 6.83 (dd, J= 7.2 and 2.0 Hz, 1H), 7.00 (d, J=7.2 Hz, 1H), 7.08 (d, J=2.0 
Hz, 1H), 7.24 (m, 5H), 7.86 (s, 1H). 13C-NMR (CDCl3) : 51.07, 54.85, 55.32, 55.43, 
60.10, 64.85, 93.13, 94.86 (2C), 110.39, 113.50, 113.63, 122.99, 126.21 (2C), 126.87, 
128.36 (2C), 130.18, 131.19, 138.78, 139.63, 140.18, 152.99 (2C), 159.05, 161.99. MS 
(ESI): [M+1]+=477.5. Anal. calcd for C27H28N2O6: C, 68.05; H, 5.92; N, 5.88; found: C, 
67.89; H, 5.73; N, 5.65. 
5.1.6.26. Methyl 6-methoxy-1-methyl-3-[(3,4,5-trimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3z). Following general procedure E, the crude residue obtained from 11p 
and 3,4,5-trimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 3:7 (v:v) as eluent, to furnish 3z as a yellow solid. Yield: 54%, 
mp 156-158 °C. 1H-NMR (DMSO-d6) : 3.55 (s, 3H), 3.56 (s, 6H), 3.79 (s, 3H), 3.89 
(s, 3H), 4.14 (s, 3H), 4.14 (s, 2H), 6.82 (d, J=9.2 Hz, 1H), 6.88 (m, 2H), 7.67 (bs, 1H). 
13C-NMR (DMSO-d6) : 35.30, 51.97, 55.88 (2C), 56.11, 60.61, 94.20 (2C), 106.75, 
114.64, 118.02, 119.94, 122.78, 128.34, 129.13, 131.07, 141.61, 148.12, 153.50 (2C), 
162.59. MS (ESI): [M+1]+=401.3. Anal. calcd for C21H24N2O6: C, 62.99; H, 6.04; N, 
7.00; found: C, 62.77; H, 5.78; N, 6.78. 
5.1.6.27. Methyl 5-methoxy-1-methyl-3-[(3,5-dimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3aa). Following general procedure E, the crude residue obtained from 11c 
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and 3,5-dimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3aa as a yellow solid. Yield: 49%, 
mp 89-90 °C. 1H-NMR (DMSO-d6) : 3.61 (s, 6H), 3.65 (s, 3H), 3.79 (s, 3H), 3.92 (s, 
3H), 5.91 (d, J=2.4 Hz, 1H), 5.97 (d, J=2.4 Hz, 2H), 6.72 (d, J=2.4 Hz, 1H), 7.01 (dd, 
J=9.6 and 2.4 Hz, 1H), 7.51 (d, J=9.2 Hz, 1H), 7.70 (s, 1H). 13C-NMR (CDCl3) : 
31.94, 51.38, 54.72 (2C), 55.16, 90.81, 93.49 (2C), 101.16, 112.17, 116.95, 118.45, 
120.85, 125.69, 133.09, 147.38, 152.90, 160.79 (2C), 161.96. MS (ESI): 
[M+1]+=371.4. Anal. calcd for C20H22N2O5: C, 64.85; H, 5.99; N, 7.56; found: C, 64.67; 
H, 5.78; N, 7.34. 
5.1.6.28. Ethyl 5-methoxy-1-methyl-3-[(3,5-dimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3ab). Following general procedure E, the crude residue obtained from 11g 
and 3,5-dimethoxyaniline was purified by flash chromatography, using ethyl 
acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3ab as a yellow solid. Yield: 45%, 
mp 106-107 °C. 1H-NMR (CDCl3) : 1.21 (t, J=7.2 Hz, 3H), 3.61 (s, 6H), 3.67 (s, 3H), 
3.93 (s, 3H), 4.22 (q, J=7.2 Hz, 2H), 5.89 (d, J=2.0 Hz, 1H), 5.94 (s, 2H), 6.78 (d, 
J=2.0 Hz, 1H), 7.01 (dd, J=9.6 and 2.8 Hz, 1H), 7.51 (d, J=9.2 Hz, 1H), 7.65 (s, 1H). 
13C-NMR (CDCl3) : 13.88, 31.96, 54.73 (2C), 55.18, 60.09, 90.63, 93.17 (2C), 100.86, 
112.17, 116.95, 118.96, 121.28, 125.49, 132.98, 147.79, 153.06, 160.84 (2C), 161.52. 
MS (ESI): [M+1]+=385.03. Anal. calcd for C21H24N2O5: C, 65.61; H, 6.29; N, 7.29; 
found: C, 65.48; H, 6.16; N, 7.09. 
5.1.6.29. n-Propyl 5-methoxy-1-methyl-3-[(3,5-dimethoxyphenyl)amino]-1H-indole-2-
carboxylate (3ac). Following general procedure E, the crude residue obtained from 11i 
and 3,5-dimethoxyaniline was purified by flash chromatography, using ethyl 
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acetate:petroleum ether 2:8 (v:v) as eluent, to furnish 3ac as a yellow solid. Yield: 42%, 
mp 83-85 °C. 1H-NMR (DMSO-d6) : 0.87 (t, J=7.2 Hz, 3H), 1.62 (m, 2H), 3.61 (s, 
6H), 3.66 (s, 3H), 3.93 (s, 3H), 4.16 (q, J=6.6 Hz, 2H), 5.89 (d, J=1.8 Hz, 1H), 5.94 (d, 
J=1.8 Hz, 2H), 6.76 (d, J=2.2 Hz, 1H), 7.02 (d, J=9.4 and 2.2 Hz, 1H), 7.50 (d, J=9.4 
Hz, 1H), 7.62 (s, 1H). 13C-NMR (CDCl3) : 10.38, 21.36, 32.01, 54.72 (2C), 55.18, 
65.67, 90.64, 93.16 (2C), 100.89, 112.19, 116.96, 118.98, 121.21, 125.48, 133.00, 
147.67, 153.03, 160.82 (2C), 161.63. MS (ESI): [M+1]+=399.3. Anal. calcd for 
C22H26N2O5: C, 66.32; H, 6.58; N, 7.03; found: C, 66.06; H, 6.36; N, 6.88. 
5.2. Biological assays and computational studies. 
5.2.1. Cell growth conditions and antiproliferative assay. 
Human cervix carcinoma (HeLa), human colon carcinoma (HT29), human breast 
carcinoma (MCF-7) and human promyelocytic leukemia (HL-60) cells (3-5 x 104 cells) 
and a serial (5-fold) dilution of the test compounds were added to a 96-well microtiter 
plate. The cells were incubated for 72 h at 37 °C in a humidified 5% CO2 atmosphere. At 
the end of the incubation period, the cells were counted in a Coulter Counter (Coulter 
Electronics Ltd, Harpenden Herts, United Kingdom). The IC50 (50% inhibitory 
concentration) was defined as the concentration of compound that inhibited cell 
proliferation by 50%. The IC50 values represent the average (± standard deviation) of 
three independent experiments. Human peripheral blood mononuclear cells (PBMC) 
were obtained from healthy donors by centrifugation with Ficoll-Paque Plus (GE 
Healthcare Bio-Sciences AB, Uppsala). 
5.2.2. Effects on tubulin polymerization and on colchicine binding to tubulin.  
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Bovine brain tubulin was purified as described previously [47]. To evaluate the effect of 
the compounds on tubulin assembly in vitro [48], varying concentrations were 
preincubated with 10 M tubulin in 0.8 M glutamate buffer at 30 ˚C and then cooled to 
0 ˚C. After addition of GTP, the mixtures were transferred to 0 C cuvettes in a 
recording spectrophotometer and warmed to 30 °C, and the assembly of tubulin was 
observed turbidimetrically. The IC50 was defined as the compound concentration that 
inhibited the extent of assembly by 50% after a 20 min incubation. The capacity of the 
test compounds to inhibit colchicine binding to tubulin was measured as described earlier 
[49], except that the reaction mixtures contained 0.5 M tubulin, 5 M [3H]colchicine 
and 5 or 0.5 M test compound. 
5.2.3. Molecular modeling.  
All molecular docking studies were performed on a Viglen Genie Intel®CoreTM i7-3770 
vPro CPU@ 3.40 GHz x 8 running Ubuntu 14.04. Molecular Operating Environment 
(MOE) 2018.10 [50] and Maestro (Schrödinger Release 2017-1) [51] were used as 
molecular modeling software. The tubulin structures were downloaded from the PDB 
data bank (http://www.rcsb.org/; PDB code 5BMV, 4O2B, 5LYJ). The proteins were 
preprocessed using the Schrödinger Protein Preparation Wizard by assigning bond 
orders, adding hydrogens and performing a restrained energy minimization of the added 
hydrogens using the OPLS_2005 force field. Ligand structures were built with MOE 
2018.10 and then prepared using the Maestro LigPrep tool by energy minimizing the 
structures (OPLS_2005 force field), generating possible ionization states at pH 7±2, 
generating tautomers and low-energy ring conformers. After isolating a tubulin dimer 
structure, three different 12 Å docking grids (inner-box 10 Å and outer-box 22 Å) were 
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prepared using as centroid the co-crystallized colchicine in the 4O2B structure, the co-
crystallized CA-4 in the 5LYJ protein and the Asn249 in the 5BMV structure. 
Ensemble docking studies were performed using Maestro Virtual Screening Workflow 
tool, setting Glide SP precision as docking score, 6 as number of outputs poses per input 
ligand to include in the solution and retaining all good scoring states. The output poses 
were saved as sdf files. The docking results were visually inspected in MOE2018.10 for 
their ability to bind in the active site. Superposition of the tubulin crystal structures was 
performed using the Alignment/Superpose tool in MOE2018.10. 
5.2.4. High content imagining of cell cycle distribution.  
HeLa cells were seeded at 5000 cells per well in 96 well clear flat bottom tissue culture 
plates. After overnight incubation, the cells were treated with the test compounds at six 
different concentrations ranging from 6.4x10-4 to 2 µM for 24 h. Cells were then fixed 
with 4% PFA in PBS for 10 min, washed and the nuclei stained by adding a solution of 
300 nM 4′,6-diamidino-2-phenylindole (DAPI, Molecular Probes). The plates were 
imaged on a CX5 High Content Screening device (ThermoFisher Scientific), using the 
Cell Cycle Analysis bio-application. A minimal of 500 cells was imaged for each well.  
5.2.5. Apoptosis assay. 
HeLa cells were seeded at 1500 cells per well and PBMC at 28000 cells per well in 384 
well black-walled, clear-bottomed tissue culture plates containing the test compounds at 
different concentrations ranging from 6.4x10-4 to 10 µM. Both IncuCyte® Caspase 3/7 
Green Reagent and IncuCyte® NucLight Rapid Red were added as recommended by the 
supplier, and the plates were incubated and monitored at 37 °C for 3 days in an 
IncuCyte® (Essen BioScience Inc., Ann Arbor, MI, USA) for real-time imaging. Images 
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were taken every 3 h, with one field imaged per well under 10x magnification. The 
compounds were tested in two independent experiments, with the PBMCs originating 
from two different blood donors. 
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